

ROCHE – WE INNOVATE HEALTHCARE. LET US INSPIRE YOUR CAREER.

Headquartered in Basel, Switzerland, Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As a supplier of innovative products and services for the early detection, prevention, diagnosis and treatment of disease, the Group contributes on a broad range of fronts to improving people's health and quality of life. Roche is a world leader in diagnostics, the leading supplier of medicines for cancer and transplantation and a market leader in virology.

We all dream of making a difference, improving people's lives. At Roche, we have the resources, vision and passion to transform dreams into fulfilling careers.

We offer exciting career opportunities, both locally and internationally, within a culture that is supportive and rewarding. We value the contribution our employees make to Roche's success, and we aim to create a work environment where feeling valued, respected and empowered is a daily experience.

Find out more about careers at Roche.
<http://careers.roche.com>



We Innovate Healthcare

YEARBOOK 2008

Medicinal Chemistry in Europe YEARBOOK 2008

EUROPEAN FEDERATION
FOR MEDICINAL CHEMISTRY



Letter from the President

Writing this second Editorial represents a suitable moment to have our traditional 'look back and forward' to important events in our European Federation for Medicinal Chemistry.

Let's start with some of the meetings that our Federation has sponsored this past year. The first one, the International Symposium on Advances in Synthetic and Medicinal Chemistry (ASMC), was jointly organized by the EFMC and ChemBridge Corporation with the sponsorship of ACS and held in St. Petersburg, Russia, from August 27 to 31, 2007. With more than 600 participants from 42 countries, this second edition of the ASMC has repeated the success of the first edition that was held in Moscow in 2004, thus confirming the validity of its formula, characterized by an unusual blend of avant-garde topics from the two sister disciplines of organic and medicinal chemistry. The successful outcome of this event is certainly due to the efforts of many people. Here I wish to thank, in particular Steve Ley (University of Cambridge) and Magid Abou-Gharbia (Wyeth Research), Gene Vaisberg and Sergey Altshteyn (ChemBridge Corporation), and Edmond Differding (UCB) for their invaluable contribution. It is my wish and that of all EFMC that this series of meetings will continue and we are looking forward to the 2009 Edition.

This year has also seen the launch of a new series of meetings to be organized jointly every two years by the ACS-Medi Division and EFMC in collaboration, each time, with the national society of a European country. The aim of this initiative is to bring together

leading US and European medicinal chemists from academia and industry in a meeting intended to build collaborative bridges among the participants, while highlighting recent advances the drug discovery and the medicinal chemistry of chosen topics. The first of these meetings has been organized in Italy in collaboration with the Division of Medicinal Chemistry of the Italian Chemical Society and held in Siena, from October 7 to 9, 2007 in the spectacular venue of S. Maria della Scala under the title of Frontiers in CNS and Oncology Medicinal Chemistry. It has been a greatly successful meeting from both scientific and organisation points of view and I wish to thank here, in particular, Giovanni Gaviraghi (Siena Biotech) and Dave Rotella (ACS-Medi Division) for their key role in organizing a meeting that has seen 200 participants from 20 countries and has proven to be very successful from both a scientific and an organisation point of view. The second meeting is planned for the second half of 2009 and the first organisation details will shortly appear in the ACS and EFMC websites.

Let me remember, finally, the 5th Joint Meeting on Medicinal Chemistry (JMMC) held in June in Portorož, in the Slovenian Adriatic and organized in a splendid way by Daniel Kikelj. I again congratulate him and his collaborators for their successful achievement.

Among the events coming up for medicinal chemists in 2008, let me highlight here the XXth International Symposium on Medicinal Chemistry, EFMC-ISMC 2008 that will take place in Vienna from August 31 until September 4. Peter Ettmayer, together with the Organising Committee members, is

preparing what promises to be a new, very exciting edition in both scientific and social respects, of the most 'classical' among our symposia. For more information please have a look at www.ismc2008.org.

Among the key activities and the several events in which the EFMC has been involved during 2007 let me outline that during the Council held in June in Portorož we had the pleasure to welcome two new member organizations: the Section of Pharmaceutical/Medicinal Chemistry of the German Pharmaceutical Society and the Group of Medicinal Chemistry of the Portuguese Chemical Society. We look forward to a fruitful collaboration with both of them!

During this Council, moreover, there has been the report of the special Committee formed in order to revise and update the Federation regulations and bylaws. Among the revisions proposed and approved, the change in the composition of the Executive Committee, with a new, mandatory balance between Industry and Academia members, and the introduction in the Regulations of the recently formed Committees, seen as important, additional instruments for improving our organisation and management. I am sure, at this regard, that through the efforts of all our Committees chairs and members we will increasingly be able to focus on a mixing of the old and the new, on a blending of new ideas and memories towards our common goals of promotion, support and unity for the Federation.

Besides the introduction of the Committees a major breakthrough in our Federation has certainly been the publication of the first two issues of our newsletter 'MedChemWatch' through which the EC intends to communicate and inform our members on a regular basis. Besides this key achievement, I want to call

again your attention on the website of our federation. All organized and sponsored events, call for nominations, awards, a complete list of functions of our Federation and the MedChemWatch issues can be viewed at www.efmc.info. It will be with your participation and support that our website will function as an effective hub of communication and information for and about our members, thus elevating the visibility of our federation.

The Federation presents several major Awards on a biennial basis. These are the Nauta Award for Pharmacochimistry, the UCB-Ehrlich Award for Excellence in Medicinal Chemistry and the Prous Institute - Overton and Meyer Award for New Technologies in Drug Discovery. I would like to strongly encourage EFMC members to follow the call for nominations and to submit candidates for the Awards which will be conferred on the occasion of the XXth EFMC-ISMIC in Vienna. You can have all the information regarding the Awards by consulting our website.

Our agenda for this and for the coming year is by no means final and we are always happy to hear ideas and proposals which may be incorporated into our activities. Please feel free, at this regard, to contact me or any of the Committee Chairs which are listed on our website. With everyone's help I look forward to a new productive year creating experiences which will enhance our profession and our Federation.

December holidays are just ahead. I hope that they are filled with good health and happiness for each of you and your families.

Sincerely,

Roberto Pellicciari,
President, EFMC

CORPORATE MEMBERS

EFMC offers any company the opportunity to become an official corporate sponsor. Corporate membership will help the EFMC with its objective of advancing the science of medicinal chemistry and can be achieved in several ways:

- by making a cash donation of at least 2500 Euros
- by sponsoring an official EFMC award
- by providing EFMC travel grants for attending the ISMC
- by sponsoring an EFMC international conference

Corporate Members will be acknowledged by the Federation in its primary literature and website, which will include their logo. In addition, a link to the company careers website will be included on the EFMC web-site free of charge. They will also be eligible for an expanded entry in the 'Directory of Companies' in the EFMC Yearbook "Medicinal Chemistry in Europe", distributed to more than 6 500 medicinal chemists in Europe annually. Their nominee will also be invited to participate in round-table discussions organised during the biennial ISMC and can be proposed to join conference committees.

Anyone interested in their company becoming a Corporate Member should contact Dave Alker at davidalker@btinternet.com

ASTRAZENECA



BENTHAM



BOEHRINGER

Austria – Germany - Italy




CHEMBRIDGE



JOHNSON & JOHNSON
PHARMACEUTICAL
RESEARCH & DEVELOPMENT



Prof. Dr. W. Th.
Nauta Foundation



NOVARTIS



PFIZER




PROUS



SERVIER



UCB




WYETH





BOROCHEM

boron building blocks for chemist



• BORONIC ACIDS
AND ESTERS

• CUSTOM
SYNTHESIS

• NEW BORONATED
BIOACTIVE
MOLECULES

QUALITY

RELIABILITY

INNOVATION

FROM MG TO KG

*Experts in
Boron Chemistry*

BOROCHEM

Immeuble Emergence

7, rue Alfred Kastler - 14000 Caen - France

Tél +33 231 945 073 - Fax +33 231 462 651

info@borochem.fr - www.borochem.fr

TABLE of Content

EFMC Presentation

National Adhering Organisations

Directory of Companies

01	Editorial
03	Corporate Members
05	Table of Content
07	Executive Committee 2008
08	Council
09	EFMC Objectives
10	Education and Training Committee
	European Committee R&D
11	Initiatives Committee
12	Industry Liaison Committee
13	Information & Communication
16	EFMC Awards
19	Calendar of Events
25	Article
34	Austria
35	Belgium
38	Denmark
39	France
41	Germany
43	Greece
44	Hungary
45	Israël
46	Italy
47	Latvia
48	Poland
49	Portugal
50	Russia
51	Slovenia
52	Spain
54	Sweden
55	Switzerland
56	The Netherlands
57	Turkey
58	United Kingdom
60	Directory of companies

Publisher: Medicinal Chemistry in Europe,
the Yearbook of the European Federation for Medicinal
Chemistry is published by:

LD Organisation,
Scientific Conference Producers
Route de Blocry, 55
BE-1348 Louvain-la-Neuve, Belgium
Tel: +32 10 45 47 77 - Fax: +32 10 45 97 19
Email: efmc@ldorganisation.com

Reproduction:
All items published in this directory are protected
by copyright. Reproduction by reprint, photocopy,
microfilm or any other process is not allowed
without the prior written permission of the publisher.

www.efmc.info



COMBINING INNOVATION AND EXPERIENCE



Johnson & Johnson
PHARMACEUTICAL RESEARCH
& DEVELOPMENT
DIVISION OF JANSSEN PHARMACEUTICA N.V.

Across the globe, around the clock,
Johnson & Johnson Pharmaceutical Research & Development
is committed to improving the lives of millions.

www.jnjpharmarnd.com

EXECUTIVE COMMITTEE

PRESIDENT

Prof. Dr. Roberto PELLICCIARI
UNIVERSITY OF PERUGIA
Dipartimento di Chimica e Tecnologia del Farmaco
Via del Liceo 1
06123 Perugia Italy
Tel: +39 075 585 51 20 / +39 075 585 5164
Fax: + 39 075 585 51 24
rp@unipg.it



PRESIDENT ELECT

Prof. Dr. Gerhard ECKER
UNIVERSITY OF VIENNA
Department of Medicinal Chemistry
Althanstrasse 14
1090 Vienna Austria
Tel: +43 1 4277 55110
Fax: +43 14277 9551
gerhard.f.ecker@univie.ac.at



SECRETARY/TREASURER

Dr. Rasmus CLAUSEN
UNIVERSITY OF COPENHAGEN
Department of Medicinal Chemistry
Universitetsparken 2
2100 Copenhagen Denmark
Tel: +45-35336566
Fax: +45 35306040
rac@dfuni.dk



MEMBER

Dr. David ALKER
The Biological and Medicinal Chemistry Sector (BMCS)
of the Royal Society of Chemistry (RSC) (President)
DAVID ALKER ASSOCIATES
19, Shakespeare Road, Birchington
CT7 9ET Kent United Kingdom
Tel: +44-1843-845-783
davidalker@btinternet.com



MEMBER

Dr. Brigitte LESUR
INSTITUT DE RECHERCHES SERVIER
125, Chemin de Ronde
78290 Croissy sur Seine France
Tel: +33 1 55 72 26 16
Fax: +33 1 55 72 25 66
brigitte.lesur@fr.netgrs.com



MEMBER

Prof. Dr. Péter MÁTYUS
Organic and Medicinal Chemistry Division (OMCD)
of the Hungarian Chemical Society (HCS) (President)
SEMELWEIS UNIVERSITY
Högyes E.u.7.
1092 Budapest Hungary
Tel: +36-1-2170-851
Fax: +36-1-2170-851
peter.matyus@szerves.sote.hu



COUNCIL

The Council consists of the members of the EC and one delegate of each Adhering Organisation.

According to the new statutes, the voting rights are allotted according to the following rules: members of the EC: 1 vote, countries with up to 99 members: 2 votes, countries with 100-199 members: 3 votes, countries with 200-399 members: 4 votes, countries with 400-599 members: 5 votes, countries with 600-899 members: 6 votes, countries with more than 899 members: 7 votes. As for countries with more than one Adhering Organisation, votes will be proportionally distributed among them, taking into account their respective memberships. The resulting number will be rounded off to the closest digit.

MEMBERS:

DR. DAVID ALKER

Executive Committee

DR. RICHARD ARMER

Oxagen Ltd
Society for Medicines Research, SMR, UK

PROF. KOEN AUGUSTYNS, Universiteit Antwerpen
Medicinal and Bioorganic Chemistry Division of Royal Flemish Chemical Society (KVCV), Belgium

DR. DEREK BUCKLE

DRB Associates
The Biological and Medicinal Chemistry Sector (BMCS) of the Royal Society of Chemistry (RSC), UK

DR. EDMOND DIFFERDING

UCB
Société Royale de Chimie (SRC), Medicinal Chemistry Division, Belgium

DR. RASMUS CLAUSEN, University of Copenhagen
Executive Committee

PROF. DR. BERND CLEMENT

Universität Kiel
German Pharmaceutical Society, Section of Pharmaceutical/Medicinal Chemistry, Germany

PROF. GUNARS DUBURS

Latvian Institute of Organic Synthesis
Latvian Association for Medicinal Chemistry, Latvia

PROF. GERHARD ECKER, University of Vienna
Executive Committee

DR. PETER ETTMAYER, Boehringer Ingelheim Austria GmbH
Austrian Chemical Society, Medicinal Chemistry Section, Austria

DR. MARINA GORDALIZA, Universidad de Salamanca
Sociedad Española de Química Terapéutica, Spain

DR. ANDERS KARLEN, Uppsala University
The Swedish Academy of Pharmaceutical Sciences, Section for Medicinal Chemistry, Sweden

PROF. KATARZYNA KIEC-KONONOWICZ

Jagiellonian University, Medical College
Medicinal Chemistry Section of the Polish Chemical Society, Poland

PROF. DANIJEL KIKELJ

University of Ljubljana
Section for Medicinal Chemistry of the Slovenian Pharmaceutical Society, Slovenia

PROF. OLIVIER LAFONT

Faculté de Médecine et de Pharmacie de Rouen
Société de Chimie Thérapeutique, France

DR. BRIGITTE LESUR, Institut de Recherches Servier
Executive Committee

PROF. PÉTER MÁTYUS, Semmelweis University
Executive Committee

DR. PETER MOHR

Hoffmann-La Roche AG
Division for Medicinal Chemistry (DMC), Swiss Chemical Society (SCS), Switzerland

PROF. RUI MOREIRA

University of Lisbon
Group of Medicinal Chemistry of the Portuguese Chemical Society, Portugal

PROF. LUISA MOSTI

University of Genova
Division of Medicinal Chemistry of the Italian Chemical Society (Società Chimica Italiana), Italy

PROF. ROBERTO PELLICCIARI, Università di Perugia
Executive Committee

PROF. M. FETHI SAHIN

Gazi University
Turkish Association of Medicinal and Pharmaceutical Chemistry, Turkey

PROF. GERD SCHNORRENBERG

Boehringer Ingelheim Pharma KG
Division of Medicinal Chemistry of the German Chemical Society (GDCh), Germany

DR. JEFFREY STERLING

TEVA Pharmaceutical Ind
The Medicinal Chemistry Section of the Israel Chemical Society, Israel

PROF. KRISTIAN STRØMGAARD

The Danish University Of Pharmaceutical Sciences
The Danish Society for Pharmacology and Toxicology, Denmark

PROF. HENK TIMMERMAN

Vrije Universiteit LACDR
Section of Pharmacochimistry, Royal Netherlands Chemical Society (KNCV), The Netherlands

ASSOC. PROF. ANNA TSANTILI-KAKOULIDOU

University of Athens
Hellenic Society of Medicinal Chemistry, Greece

DR. JÁNOS WÖFLING

University of Szeged
Organic and Medicinal Chemistry Division (OMCD) of the Hungarian Chemical Society (HCS), Hungary

PROF. NIKOLAY S. ZEFIROV

Moscow State University
The D.I. Mendeleev Russian Chemical Society, Medicinal Chemistry Section, Russia

The **European Federation for Medicinal Chemistry (EFMC)** is an independent association founded in 1970. Free from any political convictions, it represents the scientific organisations from 23 European countries and covers a geographical area the size of the USA with a similar scientific population. Its objective is to advance the science of Medicinal Chemistry by promoting cooperation and encouraging strong links between the National Adhering Organisations, in order to promote contacts and exchanges between medicinal chemists in Europe and around the World. Moreover, it offers medicinal chemists an opportunity to present their work internationally by organising the biennial International Symposium on Medicinal Chemistry (ISMC). These symposia, with an average attendance of 1,400 delegates, are highly international with a broad range of speakers and attendees representing well in excess of 40 countries.

The EFMC pursues its activities via the Executive Committee, the Council and 4 committees: Education and Training Committee, Industry Liaison Committee, European Commission R&D Initiatives Committee, and Information & Communication Committee.

These Committees strengthen the links between Council and EC and help to define the mission, vision and goals of EFMC.

The EFMC has very strong links with the Medicinal Chemistry Division of the American Chemical Society. The EFMC has a permanent representative at its management meetings and also has a permanent representative on the Long Range Planning Committee of the ACS Medicinal Chemistry Division. Through this collaboration the ACS convenes sessions for the biennial ISMC Symposia, and conversely the EFMC convenes sessions for ACS National meetings. This reciprocal relationship is continually strengthened and recently extended to the joint organisation of

a bilateral meeting. Furthermore, the EFMC has a specific representative on the Editorial Advisory Board of the Journal of Medicinal Chemistry, thus demonstrating the quality of European science and its scientists. EFMC also has strong links with the European Federation for Pharmaceutical Sciences. Besides exchanging sessions at various scientific congresses, EFMC and EUPES joined forces in establishing an European Pharmaceutical Sciences Leadership Forum. In addition, the EFMC also collaborates with the Asian Federation of Medicinal Chemistry by participating in meetings organised by the AFMC and vice versa, giving the EFMC a broad international footprint.

An important part of the EFMC activities is sponsorship of national scientific meetings organised between two or more countries. Supported by Bentham, it also awards bursaries for younger scientists to attend ISMC meetings. The EFMC also acknowledges the excellence of medicinal chemists' work, by conferring three major awards: the Nauta Award on Pharmacochimistry, the UCB-Ehrlich Award for Excellence in Medicinal Chemistry and the Prous Institute-Overton and Meyer Award for New Technologies in Drug Discovery, which are given every two years for outstanding achievements in the field of Medicinal Chemistry.

The EFMC homepage is now hot-wired to the web sites of many national organisations, thus facilitating the flow of information, and the yearbook "Medicinal Chemistry in Europe" should help to further develop cooperation between member organisations as well as their industrial partners and therefore advance medicinal chemistry in Europe, and by extension around the globe.

EDUCATION AND TRAINING COMMITTEE

COMMITTEE MEMBERSHIP:

- **Péter MÁTYUS – ETC Chair** (EFMC Executive Committee member)
- **Dave ALKER** (EFMC Executive Committee member, Point Contact for EFMC Corporate Membership)
- **Sylviane GIORGI-RENAULT** (Member of SCT, France)
- **Marina GORDALIZA** (Council Member)
- **Danijel KIKELJ** (Council Member)
- **Guiseppe RONSISVALLE** (Council Member)
- **Feheti SAHIN** (Council Member)
- **Henk TIMMERMAN** (Council Member, EFMC Executive Committee Advisor)
- **Anna TSANTILI** (Council Member)

COMMITTEE OBJECTIVE:

To ensure the training of the next generation of medicinal chemists within Europe at both the undergraduate and postgraduate levels, based on strong industry-academia cooperation, and to provide a platform to address future development training needs

COMMITTEE GOALS:

- Undertake a comprehensive analysis of the structure and profile of European teaching and education systems for medicinal chemistry
- Agree the core skills a medicinal chemist should acquire during their Masters level and PhD level training
- Quantify existing undergraduate and postgraduate level training courses within Europe
- Identify best practice from this analysis and publish an overview and conclusions
- Summarise career destinations for Masters and PhD level medicinal chemists, and identify core skills gaps in each country from both the industrial and academic perspective
- Identify deficiencies in the current teaching and education of medicinal chemistry in Europe, and establish means of addressing these

- Summarise currently available software for e-learning of medicinal chemistry

- Continue to support the current residential postgraduate Medicinal Chemistry Schools (training courses) in Italy, the Netherlands and Switzerland

- Facilitate the establishment of additional local residential Medicinal Chemistry Schools in other European countries

- Incorporate medicinal chemistry trends in future Medicinal Chemistry Schools

- Include sessions on the teaching and education of medicinal chemistry on a regular basis in EFMC-sponsored symposia

- Hold a satellite session at each ISMC on the future trends and direction of medicinal chemistry

- Raise the awareness and importance of appropriate medicinal chemistry training and education with other relevant learned societies e.g. IUPAC, EUFEPS

In order to achieve these challenging goals the Education Committee would welcome your knowledge, experience and ideas. If you wish to contribute towards our objectives, please contact Peter Matyus at peter.matyus@szerves.sote.hu

EUROPEAN COMMISSION R&D INITIATIVES COMMITTEE

CURRENT COMMITTEE MEMBERSHIP:

- **Ferran SANZ – Chair** (Universitat Pompeu Fabra, Spain)
- **Maria José CAMARASA** (CSIC; President of Spanish Society of Medicinal Chemistry)
- **Giovanni GAVIRAGHI** (Siena Biotech, Italy)
- **Peter ETTMAYER** (EFMC Council Member, Austria)
- **Katarzyna KIEĆ-KONONOWICZ** (EFMC Council Member, Poland)
- **Hans Peter MAERKI** (Roche, Switzerland)
- **Hans-Ulrich STILZ** (Aventis; President of German Society of Medicinal Chemistry)
- **Geoffrey STEMPE** (GlaxoSmithKline, UK)
- **Nico VERMEULEN** (Leiden Drug Research Center, The Netherlands)

COMMITTEE OBJECTIVE:

To improve and strengthen the contacts of EFMC to the European Commission in order to increase the visibility of the EFMC and its activities. Main goal in the near future will be to provide information about the Innovative Medicines Initiative to the Member Societies and to establish a platform for communicating the strengths and needs of Medicinal Chemistry to the European Commission. In addition, the ECIC Committee will also act as a forum for discussing and promoting R&D initiatives important for Medicinal Chemistry in Europe.

COMMITTEE GOALS:

- To strengthen and improve communication with the European Commission
- To support the National Adhering Organisations by ensuring that information on European R&D initiatives is communicated in an efficient and timely manner.
- To provide a platform for dissemination of activities related to the Innovative Medicines Initiative
- To communicate the strengths and needs of Medicinal Chemistry to the European Commission and other authorities
- To promote Medicinal Chemistry R&D initiatives throughout Europe

In order to achieve these challenging goals the committee is open to suggestions and comments. Please send your ideas to Ferran Sanz at fsanz@imim.es

CURRENT COMMITTEE MEMBERSHIP:

- **Brigitte LESUR – ILC Chair** (EFMC Executive Committee member)
- **Dave ALKER** (EFMC Executive Committee member, Point Contact for EFMC Corporate Membership)
- **Henk TIMMERMAN** (Council member, EFMC Executive Committee Advisor)
- **Derek BUCKLE** (Council member)

COMMITTEE OBJECTIVE:

To promote and improve liaison and cooperation between EFMC and Industry so that the EFMC can better achieve its over-arching objective to advance the science of medicinal chemistry. This includes increasing the visibility of EFMC activities within companies which employ medicinal chemists as well as those related industries for whom medicinal chemistry is an enabling science or for whom medicinal chemists represent a significant customer base.

COMMITTEE GOALS:

- To act as a link between industry and academia for the exchange of ideas, information and knowledge on medicinal chemistry
- To understand and champion the views of industry within EFMC and, where appropriate, to promote these on a wider, European stage
- To provide a forum for industrial and academic medicinal chemists to discuss the evolution of medicinal chemistry in Europe

- To promote opportunities for:
 - Short-term (up to 12 month) training periods in industry for students
 - Partnership/collaborative programmes in medicinal chemistry research topics
 - Industry/academia joint grants and sponsorship programmes
- Longer term to the committee to set up a system for job offers and candidate CV through the EFMC web-site
- Longer term to set up a directory of European centres of specific expertise in drug research

In order to achieve these challenging goals the ILC would welcome new committee members. If you are interested please contact either Brigitte Lesur blesur@hotmail.fr or Dave Alker dabidalker@btinternet.com

INFORMATION & COMMUNICATION COMMITTEE

CURRENT COMMITTEE MEMBERSHIP:

- Gerhard ECKER – ICC Chair (EFMC Executive Committee member, Austria)
- Koen AUGUSTYNS (University of Antwerp, Belgium)
- Erden BANOGLU (Gazi University, Turkey)
- Gabriele COSTANTINO (University of Perugia, Italy)
- Anders KARLEN (EFMC Council Member, Sweden)
- Olivier LAFONT (EFMC Council Member, France)
- Jordi MESTRES (Universitat Pompeu Fabra, Barcelona, Spain)
- Kristian STROMGAARD (EFMC Council Member, Denmark)

COMMITTEE OBJECTIVE:

To improve and strengthen the communication to the EFMC member societies and individual Medicinal Chemists. The main goals are to increase the visibility of the EFMC and its activities via extensive use of internet-based technology and to establish an information platform for all issues related to Medicinal Chemistry in Europe. In addition, the ICC Committee will also support the other Committees in coordinating their activities and disseminating information.

COMMITTEE GOALS:

- To strengthen and improve communication with our National Adhering Organisations
- To support the National Adhering Organisations by ensuring that their information is communicated electronically in an efficient manner via EFMC channels
- To provide a Web-portal for Medicinal Chemistry activities in Europe and to broadly disseminate information on EFMC sponsored events

- To edit and distribute MedChemWatch, the official e-Newsletter of EFMC
- To explore possibilities for creating benefits for Corporate Members and individual Medicinal Chemists who are members of our National Adhering Organisations

In order to achieve these challenging goals the committee is open to suggestions and comments. Please send your ideas to Gerhard Ecker gerhard.f.ecker@univie.ac.at

The official EFMC e-newsletter
MedChemWatch

EFMC · ISMC 2008 XXTH INTERNATIONAL SYMPOSIUM ON MEDICINAL CHEMISTRY

Vienna, Austria - August 31 – September 4, 2008



Symposium Secretariat:

LD Organisation, Scientific
Conference Producers
55, route de Blocry,
B-1348 Louvain-la-Neuve,
Belgium
Tel.: +32 10 45 47 77
Fax: +32 10 45 97 19
secretariat@ISM2008.org

www.ismc2008.org

ORGANISING COMMITTEE

Chairman

Peter ETTMAYER
(Boehringer Ingelheim, Austria)

Members

Gerhard ECKER
(University of Vienna, Austria & EFMC)
Roberto PELLICCIARI
(University of Perugia, Italy & EFMC)
Feran SANZ
(Universitat Pompeu Fabra, Spain)
Edmond DIFFERDING
(UCB, Belgium)



Medicinal Chemistry Division of
the Austrian Chemical Society



EFMC
European Federation
for Medicinal Chemistry

CONFIRMED PLENARY LECTURERS

- Paul HERRLING**
(Novartis International, Switzerland)
- Chris DOBSON**
(University of Cambridge, UK)
- Barbara IMPERIALI**
(Massachusetts Institute of Technology, USA)
- Steven V. LEY**
(University of Cambridge, UK)
- Magid ABOU-GHARBIA**
(Wyeth Research, USA)
- GlaxoSmithKline Award
for Outstanding Achievement
in the Field of Chemical Biology**

EFMC AWARD LECTURES

- The Nauta Award for Pharmacochimistry**
- The UCB-Ehrlich Award for
Excellence in Medicinal Chemistry**
- The Prous Institute-Overton
and Meyer Award for New Technologies
in Drug Discovery**

EFMC - BENTHAM TRAVEL GRANTS

Travel grants (500 € each) are available for 10 young scientists, not older than 30 years, who will be nominated by the EFMC-ISMC 2008 International Organising Committee. Details for applications are available on the symposium website.

Deadline for submission is April 10, 2008.

SESSIONS AND SESSION COORDINATORS

- Novel Lead Finding Approaches**
Hans-Ulrich STILZ (Sanofi-Aventis, Germany)
- Chemistry Strategies to Reduce
Attrition in Drug Discovery**
Geoffrey STEMPE (GlaxoSmithKline, UK)
- Emerging Drugs**
Bernd RIEDL (Bayer Healthcare, Germany)
- Kinase Selectivity-Is it Necessary? (ACS)**
David ROTELLA (Wyeth Research, USA)
- Predictive ADME/Tox Methods:
What to Apply When?**
Scott BOYER (AstraZeneca, Sweden)
- Macromolecular and Polymeric Drugs**
Abraham J. DOMB
(Hebrew University of Jerusalem, Israel)
- Fragment-Based Drug Discovery (ACS)**
Jeffrey ALBERT (AstraZeneca, USA)
- Imaging Ligands and Biomarkers (EuFAPS)**
Pia VUORELA (Åbo Akademi University, Finland)
- Natural Products as Starting Points
in Drug Discovery**
Erden BANOGLU (Gazi University, Turkey)
- Novel Approaches for treatment
of Neurodegenerative Diseases**
Magid ABOU-GHARBIA (Wyeth Research, USA)
- Type 2 Diabetes: The Incretin System**
Koen AUGUSTYNS
(University of Antwerp, Belgium)
- Progress in COPD and Asthma Therapy**
Matthias GRAUERT
(Boehringer Ingelheim, Germany)
- Allosteric Modulation
and GPCR Drug Discovery**
Rob LEURS (VU University Amsterdam,
The Netherlands)

- Oncology**
Graham WARRELOW (UCB SA, UK)
- Immunology & Immunomodulation**
Katerina LEFTHERIS
(Bristol-Myers Squibb, USA)
- Antipsychotic Targets**
Klaus P. BØGESØ (H. Lundbeck, Denmark)
- Antivirals**
Maria Jose CAMARASA (SEQT, Spain)
- Pain**
Mark DUGGAN (Amgen, USA)
- Exploring the Chemical Space**
Herbert WALDMANN (Max Planck Institute
of Molecular Physiology, Germany)
- Stefan WETZEL** (Max Planck Institute
of Molecular Physiology, Germany)
- Chemokines**
Gerhard ECKER (University of Vienna, Austria)
- Systems Level Research Informs Drug Target
Identification and Therapy Design**
Harel WEINSTEIN (Cornell University, USA)
- New Computational Approaches
Supporting Drug Design**
Jordi MESTRES (IMIM and
Universitat Pompeu Fabra, Spain)
- Druggability of Protein-Protein Interactions**
Peter NUSSBAUMER (Novartis, Austria)
- Systems Biology & Medicinal Chemistry**
Christian NOE (University of Vienna, Austria)
- Structure Based Drug Design (AFMC)**
Esin AKI-SENER (Ankara University, Turkey)
- Modulators of Adenosine and P2Y Receptors**
Kenneth A. JACOBSON (NIDDK, USA)
- Addressing Therapeutic Complexity in Oncology
with Medicinal Chemistry**
Graeme ROBERTSON (Siena Biotech, Italy)



EFMC 2008 AWARDS

Call for nominations

DEADLINE: JANUARY 31, 2008

Nominations for these Awards consist of a nomination letter, a brief CV, including a list of selected publications and two supporting letters. The nominations should be submitted to the Chairman of the Juries, Professor Roberto Pellicciari, President of EFMC, Dipartimento di Chimica e Tecnologia del Farmaco, via del Liceo 1, 06123 Perugia, Italy.

FAX: +39 075 5855124 E-MAIL: EFMCawards@efmc.info



THE NAUTA AWARD FOR PHARMACOCHEMISTRY

For the advancement of medicinal chemistry and the development of international organizational structures in Medicinal Chemistry. The Award will be given for outstanding achievements in the field of Medicinal Chemistry.



THE UCB-EHRlich AWARD FOR EXCELLENCE IN MEDICINAL CHEMISTRY

To acknowledge and recognise outstanding research in the field of Medicinal Chemistry in its broadest sense by a young scientist. This Award has been established with the support of UCB Pharma.



THE PROUS INSTITUTE-OVERTON AND MEYER AWARD FOR NEW TECHNOLOGIES IN DRUG DISCOVERY

To encourage innovation and investigation in technological development related to drug discovery, this Award established with the support of Prous Institute will be given for the discovery, evaluation or use of new technologies.

*The Awards will be conferred on the occasion of the
XXth EFMC 'International Symposium on Medicinal
Chemistry' (ISMC) to be held in Vienna, Austria,
31st August to 4th September, 2008*



**EUROPEAN FEDERATION
FOR MEDICINAL CHEMISTRY**



GIVE YOUR RESEARCH THE ADVANTAGE IT DESERVES...



IMPACT FACTOR: 2.624*



IMPACT FACTOR: 2.538*



IMPACT FACTOR: 2.187*

*2006 Journal Citation Reports®, published by Thomson Scientific, 2007

Bioorganic & Medicinal Chemistry

- The Tetrahedron Journal for Research at the Interface of Chemistry and Biology
- Publishes international mix of highly cited papers on both chemical biology and medicinal chemistry
- Rapid Publication – from acceptance to online availability in *under 1 week*
- Increasing citations – ranked amongst the top ten most cited journals in Medicinal Chemistry*

Bioorganic & Medicinal Chemistry Letters

- The Tetrahedron Journal for Research at the Interface of Chemistry and Biology
- Publishes many cutting edge discoveries from leading pharmaceutical companies – including one of the first reported disclosures of Viagra™
- Rapid Publication – from acceptance to online availability in *under 1 week*
- Published #2 most requested article in 2005, as recognised by CAS Science Spotlight
- #2 highest cited journal in Medicinal Chemistry*

European Journal of Medicinal Chemistry

- The European publication for all aspects of Medicinal Chemistry
- Published under the auspices of the French Société de Chimie Thérapeutique (SCT)
- Publishing leading research in Medicinal Chemistry for *over 35 years*
- Online article submission – authors benefit from even faster publication times

CALENDAR

of Events

organised by the National Adhering Organisations 2008
EFMC sponsored events highlighted in orange
EFMC - ISMC events highlighted in green

YOUNG RESEARCH FELLOWS MEETING

JANUARY 31, 2008

Paris, France
www.sct.asso.fr

Organising committee:
X. Cachet, E. Braud, I. Berquet-Bestel,
F.-H. Porée, S. Routier
Contact person: Xavier Cachet
Tel: +33 1 5373 9805
xavier.cachet@univ-paris5.fr

Organised by:
Société de Chimie Thérapeutique (France)

1ST INTERNATIONAL CONFERENCE ON DRUG DESIGN AND DISCOVERY

FEBRUARY 3-6, 2008

Dubai, UAE
www.icddd.com/

Contact: Prof. Taleb Altel
Tel: +971 50 1732950 - Fax: +971 6 5585812
taltal@sharjah.ac.ae

FRONTIERS IN MEDICINAL CHEMISTRY

MARCH 2-5, 2008

Regensburg, Germany
www.gdch.de/medchem2008

Organising committee:
Buschauer, Clement, Elz, Klebe, Ottow,
Schnorrenberg, Seifert, Stilz
Contact person: Prof. Dr. Armin Buschauer
Tel: +49 941 943 4827 - Fax: +49 941 943 4820
armin.buschauer@chemie.uni-regensburg.de

Organised by:
Division of Medicinal Chemistry of the German Chemical
Society (GDCh) (Germany)
German Pharmaceutical Society, Section of Pharmaceutical/
Medicinal chemistry (Germany)

THE CHALLENGES OF MULTI-TARGET DRUG DISCOVERY

MARCH 10, 2008

The Institute of Physics
London, UK
www.confsec.co.uk

Organising committee: BMCS
Contact person: Ms Elaine Wellingham
Tel: +44 1275 853311 - Fax: +44 1275 853311
esw@confsec.co.uk

Organised by:
The Biological and Medicinal Chemistry Sector
(BMCS) of the Royal Society of Chemistry (RSC)
(United Kingdom)

**JOINT MEETING
SCT-SFC-ACADÉMIE DE PHARMACIE****MARCH 11, 2008**

ENSCP
Paris, France
www.sct.asso.fr

Organising committee: SCT board
Contact person: Hervé Galons
Tel: +33 1 5373 9684
herve.galons@univ-paris5.fr

Organised by:
Société de Chimie Thérapeutique (France)

**13TH PANHELLENIC SYMPOSIUM
ON MEDICINAL CHEMISTRY****MARCH 14-15, 2008**

Athens, Greece
www.helmedchem2008.gr

Organising committee:
Mikros E. (University of Athens), Koufaki M. (IOPC/NHFR)
Contact person: A. Tsantili-Kakoulidou
Tel: +30 210 7274530 - Fax: +30 210 7274747
tsantili@pharm.uoa.gr

Organised by:
Hellenic Society of Medicinal Chemistry (HSMC)
and Division of Organic and Medicinal Chemistry/
Association of Greek Chemists (DOMC/AGC) (Greece)

**19TH SYMPOSIUM ON MEDICINAL CHEMISTRY
IN EASTERN ENGLAND****APRIL, 2008**

Hatfield, UK
www.confsec.co.uk

Organising committee: BMCS
Contact person: Dr. A. Faller
Tel: +44 1276 483036 - Fax: +44 1276 483525
faller_andrew@lilly.com

Organised by:
The Biological and Medicinal Chemistry Sector
(BMCS) of the Royal Society of Chemistry (RSC)
(United Kingdom)

DRUGS FROM NATURAL PRODUCTS IV**APRIL 7-8, 2008**

Cambridge, UK
www.confsec.co.uk

Organising committee:
BMCS & RSC Organic Division
Contact person: Ms Elaine Wellingham
Tel: +44 1275 853311 - Fax: +44 1275 853311
esw@confsec.co.uk

Organised by:
The Biological and Medicinal Chemistry Sector
(BMCS) of the Royal Society of Chemistry (RSC) and
RSC Organic Division (United Kingdom)

**PROTEINASE 2008: FROM MOLECULES
TO MEDICINES****APRIL 21-22, 2008**

SCI
London, UK
www.soci.org

Organising committee:
BMCS & Society for Chemical Industry
Contact person: Ms Jacqui Maguire
Tel: +44 20 7598 1562 - Fax: +44 20 7235 7743
jacqui.maguire@soci.org

Organised by:
The Biological and Medicinal Chemistry Sector
(BMCS) of the Royal Society of Chemistry (RSC) and
the Society for Chemical Industry (United Kingdom)

MINISYMPOSIUM ON «DRUG TARGETING»**MAY 29, 2008**

Department of Chemistry, University of Basel,
St. Johannis-Ring 19
Basel, Switzerland

Contact person: Dr. Hans Peter Maerki
Tel: +41 61 688 5055 - Fax: +41 61 688 6459
hans_p.maerki@roche.com

Organised by:
Division for Medicinal Chemistry (DMC), Swiss Chemi-
cal Society (SCS) (Switzerland)

**PHARMACOKINETICS AND DRUG METABOLISM
FOR CHEMISTS****JUNE 11, 2008**Liverpool, UK
www.confsec.co.ukOrganising committee: BMCS
Contact person: Ms Elaine Wellingham
Tel: +44 1275 853311 - Fax: +44 1275 853311
esw@confsec.co.ukOrganised by:
The Biological and Medicinal Chemistry Sector
(BMCS) of the Royal Society of Chemistry (RSC)
(United Kingdom)**RICT 44 - RENCONTRES INTERNATIONALES
DE CHIMIE THÉRAPEUTIQUE**International Conference in Medicinal Chemistry:
Interfacing Chemical Biology, Natural Products and
Drug Discovery**JULY 2-4, 2008**Angers, France
www.medchem.frOrganising committee: Prof. Olivier Duval
Contact person: Prof. Olivier Duval
Tel: +33 2 4122 6674 - Fax: +33 2 4122 6634
olivier.duval@univ-angers.frOrganised by:
Société de Chimie Thérapeutique (France)**28TH EDITION OF THE EUROPEAN SCHOOL
OF MEDICINAL CHEMISTRY (ESMEC)****JULY 6-11, 2008**Urbino, Italy
www.esmec.euOrganising committee:
Bedini Lucia, Diamantini Giuseppe,
Salvatori Americo, Spadoni Gilberto
Contact person: Dr. Bedini Lucia
Tel: +39 0722 3033 23 - Fax: +39 0722 3033 13
chimfarm@uniurb.itOrganised by:
Division of Medicinal Chemistry of the Italian
Chemical Society (Società Chimica Italiana) (Italy)**INTERNATIONAL SYMPOSIUM ON THE INDUS-
TRIAL APPLICATIONS OF THE MÖSSBAUER EFFECT****AUGUST 17-22, 2008**Budapest, Hungary
isiameo8.orgOrganising committee:
Ernő Kuzmann and Károly Lázár
Contact person: Ernő Kuzmann
Tel: +36 1 209 0555, ext. 1152 - Fax: +36 1 372 2592
isiameo8@chem.elte.huOrganised by:
Organic and Medicinal Chemistry Division (OMCD)
of the Hungarian Chemical Society (HCS) (Hungary)**SEVENTH INTERNATIONAL CONFERENCE ON
NUCLEAR AND RADIOCHEMISTRY****AUGUST 24-29, 2008**Budapest, Hungary
www.nrc7.mke.org.huOrganising committee:
Attila Vértes and László Wojnárovits
Contact person: Beatrix Bódy
Tel: +36 1 201 6883 - Fax: +36 1 201 8056
nrc7@mke.org.huOrganised by:
Organic and Medicinal Chemistry Division (OMCD)
of the Hungarian Chemical Society (HCS) (Hungary)**METABOLIC DISORDERS - FROM BENCH TO BEDSIDE****AUGUST 28-31, 2008**Sopron, Hungary
www.metdis2008.mke.org.huSatellite symposium for the XXth EFMC-ISM
(Vienna, Austria, 31 August - 4 September, 2008)Organising committee:
Péter Mátyus (Chairman), György Jermendy (Co-chairman)
Contact person: Eszter Konrád
Tel: +36 1 201 6883 - Fax: +36 1 201 8056
mail@metdis2008.mke.org.huOrganised by:
Organic and Medicinal Chemistry Division (OMCD) of the
Hungarian Chemical Society (HCS) and the Hungarian
Diabetes Association (Hungary)

**XXTH INTERNATIONAL SYMPOSIUM
ON MEDICINAL CHEMISTRY****AUGUST 31 - SEPTEMBER 4, 2008**Vienna, Austria
www.ismc2008.orgContact person:
Dr. Peter Ettmayer
(Boehringer Ingelheim Austria GmbH)
info@ISM2008.orgOrganised by:
Austrian Chemical Society, Medicinal Chemistry
Section (Austria) on behalf of the European
Federation for Medicinal Chemistry (EFMC)**GPCRs IN MEDICINAL CHEMISTRY II****SEPTEMBER 8-12, 2008**Gothenburg, Sweden
www.confsec.co.ukOrganising committee:
BMCS & Society for Chemical Industry
Contact person: Ms Elaine Wellingham
Tel: +44 1275 853311 - Fax: +44 1275 853311
esw@confsec.co.ukOrganised by:
The Biological and Medicinal Chemistry Sector
(BMCS) of the Royal Society of Chemistry (RSC) and
the Society for Chemical Industry (United Kingdom)**INTERNATIONAL CONFERENCE ON METROLOGY
OF ENVIRONMENTAL, FOOD AND NUTRITIONAL
MEASUREMENTS****SEPTEMBER 9-12, 2008**Budapest, Hungary
www.mefnm2008-budapest.orgOrganising committee:
György Horvai (Chair),
Péter Princz (Scientific Secretary)
Contact person: Beáta Androsits
Tel: +36 1 201 6883 - Fax: +36 1 201 8056
mefnm2008@mke.org.huOrganised by:
Organic and Medicinal Chemistry Division (OMCD)
of the Hungarian Chemical Society (HCS) (Hungary)**FALL MEETING
OF THE SWISS CHEMICAL SOCIETY****SEPTEMBER 11, 2008**University of Zürich, Irchel Campus
Zürich, SwitzerlandOrganised by:
Division for Medicinal Chemistry (DMC),
Swiss Chemical Society (SCS) (Switzerland)**XIXTH NATIONAL MEETING
ON MEDICINAL CHEMISTRY****SEPTEMBER 14-18, 2008**GlaxoSmithKline Auditorium
Verona, Italy
www.nmmcverona2008.unimore.itOrganising committee:
Chairmen: Donati Daniele, Brasili Livio
Contact person: Prof. Mosti Luisa
Tel: +39 010 353 8350 - Fax: +39 010 353 8358
mosti@unige.itOrganised by:
Division of Medicinal Chemistry of the Italian
Chemical Society (Società Chimica Italiana) (Italy)**INTERFACES '08****SEPTEMBER 24-26, 2008**Sopron, Hungary
www.interfaces08.huOrganising committee:
Árpád Olvasó (Chairman),
András Kovács (Scientific Secretary)
Contact person: Beáta Androsits
Tel: +36 1 201 6883 - Fax: +36 1 201 8056
mail@interfaces08.huOrganised by:
Organic and Medicinal Chemistry Division (OMCD) of
the Hungarian Chemical Society (HCS) (Hungary)

VIII JORNADAS DE LA SEQT**OCTOBER 2008**

Carmona - Sevilla, Spain

www.seqt.orgContact person:
Dr. Felipe AlcudiaTel: +34 954 55673 5 - Fax: +34 954 55673 7
falcudia@us.esOrganised by:
Sociedad Española
de Química Terapéutica (Spain)**ANNUAL ONE DAY MEETING
ON MEDICINAL CHEMISTRY****OCTOBER 2008**

Contact:

SRC-KVCV Symposium

Tel: +32 10 45 47 77

Fax: + 32 10 45 97 19

secretariat@medchem.beOrganised by:
Medicinal and Bioorganic Chemistry Division of
Royal Flemish Chemical Society (KVCV) (Belgium)
and Société Royale de Chimie (SRC), Medicinal
Chemistry Division (Belgium)**8TH SWISS COURSE ON MEDICINAL CHEMISTRY****OCTOBER 12-17, 2008**

Leysin, Switzerland

Contact person: Prof. Beat Ernst

Tel: +41 61 267 15 51 - Fax: +41 61 267 15 52

beat.ernst@unibas.chOrganised by:
Division for Medicinal Chemistry (DMC), Swiss
Chemical Society (SCS) (Switzerland)**2ND COAST TO COAST MEETING****OCTOBER 26-29, 2008**

Poole, UK

www.confsec.co.ukOrganising committee:
BMCS & Society for Chemical Industry
Contact person: Ms Elaine Wellingham
Tel: +44 1275 853311 - Fax: +44 1275 853311
esw@confsec.co.ukOrganised by:
The Biological and Medicinal Chemistry Sector (BMCS)
of the Royal Society of Chemistry (RSC) and the Society
for Chemical Industry (United Kingdom)**17TH LACDR SCHOOL ON MEDICINAL CHEMISTRY
NOORDWIJKERHOUT, THE NETHERLANDS****OCTOBER 28-31, 2008**contact person:
Erik de VriesTel: +31-71-5274341, Fax: +31-71-5274277
e.devries@lacdr.leidenuniv.nlorganized by:
Leiden/Amsterdam Center for Drug Research**SCT ANNUAL WORKSHOP
IN MEDICINAL CHEMISTRY****DECEMBER 2008**Paris, France
www.sct.asso.frOrganising committee: Dr. Yves Rolland
Contact person: Dr. Y. Rolland
yves.rolland@fr.netgrs.comOrganised by:
Société de Chimie Thérapeutique (France)

**ALZHEIMER DISEASE
MEDICINAL CHEMISTRY SYMPOSIUM
(PART OF KNCV SPRING SYMPOSIUM)
CONGRESCESTRUM DE REEHORST, EDE,
THE NETHERLANDS**

17 APRIL 2008

contact person:

Hein Coolen

Tel: +31-294-479183, Fax: +31-295-477138
hein.coolen@solway.com

organized by:

Medicinal Chemistry Section of the Royal
Netherlands Chemistry Society (KNCV)

**4TH ANGLO-SWEDISH MEDICINAL
CHEMISTRY SYMPOSIUM**

MARCH 2009

Åre, Sweden

www.lakemedelsakademin.se

Contact person:

Ms Diana Mickels

Tel: +46 8 723 5085 - Fax: +46 8 2055 11
diana.mickels@lakemedelsakademin.se

Organised by:

Swedish Academy of Pharmaceutical Sciences
(Sweden), The Biological and Medicinal Chemistry
Sector (BMCS) of the Royal Society of Chemistry
(RSC) (United Kingdom)

**28TH NOORDWIJKERHOUT-CAMERINO-CYPRUS
SYMPOSIUM ON TRENDS IN DRUG RESEARCH
NOORDWIJKERHOUT, THE NETHERLANDS**

MAY 2009

Contact person:

Henk Timmerman

henk.timmerman@planet.nl

**XXIST INTERNATIONAL SYMPOSIUM
ON MEDICINAL CHEMISTRY**

AUGUST 2010

Brussels, Belgium

www.ismc2010.org

Contact person:

Prof. Koen Augustyns (Universiteit Antwerpen)

Dr Edmond Differding (UCB S.A.)

info@ismc2010.org

Organised by:

Medicinal and Bioorganic Chemistry Division of Royal
Flemish Chemical Society (KVCV) (Belgium)
Société Royale de Chimie (SRC), Medicinal
Chemistry Division (Belgium) on behalf of the
European Federation for Medicinal Chemistry (EFMC)

Safety-Directed Drug Design: Failures Are Successes

SCOTT BOYER

Safety Assessment

AstraZeneca R&D - 43183 Mölndal - Sweden

Tel: +46317762882

scott.boyer@astrazeneca.com

Few, if any, products undergo more safety testing and scrutiny than a pharmaceutical. This, of course, is essential as the most critical issue with regard to pharmaceuticals is the risk benefit ratio. Whilst patient benefits can be quite clear in most cases, the risk of undergoing a treatment regimen must be as carefully and broadly quantified as possible. Often this characterisation results in findings that result in discontinuation or withdrawal. Thus as drug withdrawals and experimental therapeutics that do not fulfil safety criteria during preclinical and clinical trials are regarded as 'failures', they are actually successes for patient safety and for the science base of drug discovery. The lessons learned and the data gathered during this sometimes painful process is of critical importance in buttressing future efforts against similar problems.

The failure of a drug or clinical candidate is invariably associated with a massive amount of basic science that goes into problem-solving activities. This effort, if captured and integrated into the Discovery process, can contribute to the development of better and more sophisticated approaches to discovery safety assessment and meaningful refinements in the regulation of drug development and approval. Thus, the resources and momentum behind a problem solving effort, particularly around a late-stage clinical candidate present a unique opportunity to develop a more stable and valid science base upon which to build a more rational approach to discovery safety.

What does an increase in the sophistication of a safety science base look like and to whom should it be directed? The choice of therapeutic target is one critical area and many advances have been made in recent years in the characterisation of a protein's role in various tissues. This 'target safety' aspect is not a one-time exercise to be carried out at the beginning of a project, but, as the recent experience with Vioxx has shown us, a constant vigil to relate all aspects of the complicated life of a therapeutic target to the adverse event signals coming from our preclinical and clinical studies.

THE ROLE OF THE MEDICINAL CHEMIST IN SAFETY

It is the area of chemical design that perhaps the most value can be gained from translating safety data to real, tangible decisions. This is a long, tedious process but several successful examples have been identified in which a valid set of decision-making tools can be used to warn for chemical designs that contain inherent safety liabilities. In some cases this can lead to decisions before synthesis is even undertaken. In other cases the level of confidence is lower, but the tool can spark the decision to do further experiments in more sophisticated model systems to investigate the probability of a real safety problem. The key to either of these scenarios is first, a clear strategy behind the decision-making tools such that results from a simple test (SAR, QSAR, in vitro) can be followed up and confirmed in a relevant in vivo test and second, adequate throughput to facilitate iterative design. Without this confirmation mechanism very little about the *real* risk of a compound or series can be concluded and without adequate throughput the medicinal chemist will be mired in indecision.

What kinds of safety-related decisions can be made by the medicinal chemist? There are actually many. First and foremost one should always be cognisant of the area of chemistry in which one is working, the therapeutic class of compounds, and any similarities they may

have, both in their basic structure and in their pharmacophoric makeup, to compounds with known pharmacologies. Polypharmacology, whilst desirable in some special cases (1) carries the potential to add an unnecessary burden to the drug development project and in many cases, can be identified and avoided by early searching of pharmacology datasets like PubChem (2), GVKBio (3) or BioPrint (4) or by performing broad 'secondary pharmacology' screening at highly skilled and efficient contract organisations like Cerp (5) or MDS Pharma (6). This sort of characterisation hardly ever leads to the decision to stop a chemical series, but rather aids in the identification of potential problems early enough to guide confirmatory experimentation (monitoring of blood pressure in early preclinical species for compounds active at the α_1 adrenergic receptor, for example) and allows chemistry to be changed such that liabilities can be designed out if they are judged to be serious enough.

A specific case of unwanted pharmacology, of course, is activity at the cardiac hERG K⁺ channel. Potent blockers of the hERG channel can be found in most therapeutic classes and thus few industrial medicinal chemists have escaped this problem entirely. Fortunately, there have been many advances in our understanding of hERG specificity and the physicochemical properties that drive hERG blockade. Homology models of the channel are now available and scores of papers have been published on hERG structure-activity-relationships (7). Whilst building away from hERG blockade while retaining all other properties remains a huge challenge, the combination of better foundation tools such as SAR and protein models, combined with enhanced screening technologies (8) and a constantly improving picture of the preclinical and clinical testing systems required to assess the ultimate risk of fatal arrhythmias (9) has dramatically improved our ability to successfully manage this once-difficult problem. As mentioned above, high resolution preclinical and clinical studies on causal mechanisms of safety problems allow for identification of the chemical events underlying these mechanisms.

Blockade of hERG is one of these cases and now medicinal chemists, armed with the right tools, can in most cases successfully build out hERG liabilities. A list of the full compliment of hERG-related tests is given in (10).

A few simple rules for avoiding hERG activity

Avoid extended cylinder-shaped molecules with hydrophobic cores at the ends

*

Avoid amines with a pK_a above 7

*

Avoid compounds with logP or logD values over 2

In most cases, potent activity at the hERG channel is a 'show stopper' for the project and it must be addressed. Another such endpoint is genetic toxicity. As with hERG (11), genetic toxicity (12) testing is part of a mandated set of tests that must be performed before humans are exposed to a new drug candidate. As such it must be effectively dealt with in the early phase of a project to avoid a significant issue later in the more mature project. Several very effective tools are available for the medicinal chemist that range from structural warnings (13,14,15) to SAR and QSAR models with reasonable levels of predictivity (16,17,18,19). Screens for genetic alterations also come in a number of types with the most common for drug development being the Salmonella reverse mutation, or 'Ames' test and the Mouse Lymphoma assay. Several other genetic toxicity test exist and they are listed in (20) along with their intended use and, most importantly, a current view on their ability to actually predict carcinogens.

A few simple rules for avoiding Ames activity

Avoid reactive species

*

Avoid aromatic amines or compounds that give aromatic amine metabolites

*

Avoid compounds that can produce other forms of reactive metabolites

As the last point above illustrates, reactive metabolites are a problem for drug development. Reactive metabolites (21) can either be relatively 'silent', e.g., though present in significant amounts and not cause overt problems in preclinical and early clinical studies, or they can be more direct and thereby be clearly associated with organ-based toxicities. Silent reactive intermediates like those associated with halothane have the potential to bloom into quite serious problems in the clinic as more and more patients are exposed and may become apparent only after years of use in patients. These reactions are sometimes labelled 'idiosyncratic' although in reality the seeds of a serious safety problem were already sown by the medicinal chemist. Direct, organ-based toxicity by compounds producing reactive intermediates, such as paracetamol, is also possible and is usually easier to detect early because they cause a more dose-related lesion that is seen across species and in nearly all individuals exposed. What about those compounds that produce reactive intermediates but have not been shown to produce either direct or idiosyncratic toxicities? Do these represent a set of compounds or lesions that are benign or are they examples of the safety issues of the future when enough patient experience have accumulated and/or enough overdoses have occurred? It is important for medicinal chemists to appreciate that we do not know! Thus prudence, both to avoid unnecessarily burdening the project and to act responsibly towards our future patients would dictate that we identify those functional groups that can give rise to reactive metabolites and at the very least be aware of them and preferably avoid them. Awareness can also aid the interpretation of safety studies when unexpected pathologies are observed. A catalogue of in vivo pathologies that have been associated with reactive intermediates is a very useful tool to be used in combination with a thorough library of the functional groups and substructures that can give rise to reactive intermediates.

A few simple rules for avoiding reactive intermediates

Actively use a 'warning' substructure list
*

Characterise biotransformation as early as possible
*

Look for warning signs: toxicity in genetic tox assays using metabolic activation, time-dependent inhibition of P450 activity, cytotoxicity in P450-expressing cell lines (22)
*

Assess degree of binding in combination with the intended dose. The higher the dose, the greater the reactive metabolite burden

What advice can be given to the medicinal chemist wishing to assess structures for liabilities outside these few areas? Online structure toxicity resources such as ChemIDPlus (23), IUCLID (24), TOXNET (25) and DSSTox (26) can compliment the commercial information/model tools such as MultiCASE (27) and DEREK (28). A recent, potentially useful addition to this group is the Mechanism Based Toxicity database from GVKBio (29), a hand-annotated, structure-searchable database of reported toxicities. The current version of this database contains over 13000 entries.

In vitro tests are too numerous to list here, but several new and useful test have recently been reviewed (30). The general trend is to move away from gross cytotoxicity assays in the target cell/tissue type and to instead focus on either non-lethality measures in target cell types or measurements of general interference in basic cellular processes via the monitoring of several endpoints simultaneously (31). Additionally, recent examples of promising applications of toxicogenomics give hope that this technique will finally begin to live up to the initial promise (32,33). There is an almost universal desire to enhance the predictivity of early toxicology screens and this has lead to a number of products and initiatives to improve

the general area of 'Predictive Toxicology'. But do we have the patience to validate these methods?

PREDICTIVE TOXICOLOGY: THE TWILIGHT ZONE

There are several promising technologies that are commonly lumped under the heading of 'predictive toxicology' and are, naturally, under varying stages of development and validation. Often one is exposed to these approaches and technologies too early in their development and a generally negative and sceptical attitude develops toward all predictive toxicology approaches. This is unfortunate as many of these are indeed sound basic ideas that suffer from inadequate validation and testing and/or are used for applications outside their originally intended purpose. Thus one can lament the failure rate of drugs and drug candidates, but the failure rate of predictive technologies is, in practice, probably many times higher. That said, why engage these at all? Because some of them actually appear to yield useful information, particularly if enough data are accumulated within a single chemical series to make series-specific structure-toxicity-relationships. The same risk-benefit argument that is used to justify embarking on a drug treatment can be used when committing to the exploitation of a 'predictive toxicology' technology. It may not work for everyone in all cases, but the risk of failure is worth the benefit of enlightened chemical design and the potential of project progression and/or competitive advantage. Also, the effectiveness of a new method is only truly tested with an adequate (large) number of examples; examples that may take years to accumulate. Few organisations possess this level of patience and thus the demise of potentially useful predictive toxicology approaches is usually swift and unfortunately premature.

WILL IT HELP?

Those who choose only the tried and proven methods of discovery safety assessment are in danger of missing true opportunities in the technologies of the predictive toxicology twilight zone. Conversely, those who do not fully exploit the 'fundamental' methods as a foundation upon which to base a diversity of approaches may not only be doing themselves and their organisations a disservice, but they are also neglecting the fact that toxicology data, whether it be from animals or from humans, has been produced through studies designed to explore the edges of tolerability of a drug and thus a certain degree of adversity accompanied producing the data in the first place. With that consideration, as a species with a capacity for ethical behaviour, we owe it to ourselves and our fellow species to use as much toxicology data as possible to inform and improve as many aspects of our early drug discovery decisions as possible.

With the goal of integrating as much of this rapidly expanding sophistication into chemical design, the potential for *reducing* safety-related failures exists, but is far from certain. One certain effect will be that promising compounds will fail less often for the reasons of yesterday. Rather, the problems of the future will be qualitatively different, but if we have done a conscientious job in addressing the problems of yesterday, we will free up more time and resources within our safety groups for problem-solving around more of tomorrow's problems. That, despite the real potential for continued failure, is progress and thus a success in itself.

REFERENCES

1. Paolini, G.V., Shapland, R.H., van Hoorn, W.P., Mason, J.S. & Hopkins, A.L. (2006) *Nature Biotechnology* **24**, 805-815
2. <http://pubchem.ncbi.nlm.nih.gov>
3. <http://www.gvkbio.com>
4. <http://www.cerep.fr/cerep/users/pages/collaborations/bioprint.asp>
5. <http://www.cerep.fr>
6. <http://www.mdsp.com>
7. Jamieson, C., Moir, E.M., Rankovic, Z., Wishart, G. (2006) Medicinal Chemistry of hERG Optimizations: Highlights and Hang-Ups. *Journal of Medicinal Chemistry* **49**: 5029-5046
8. Bridgeland-Taylor, M.H., Hargreaves, A.C., Easter, A., Orme, A., Henthorn, D.C., Ding, M., Davis, A.M., Small, B.G., Heapy, C.G., Abi-Gerges, N., Persson, F., Jacobson, I., Sullivan, M., Albertson, N., Hammond, T.G., Sullivan, E., Valentin, J.-P., Pollard, C.E. (2006) *Journal of Pharmacological and Toxicological Methods* **54**, 189-199
9. Hoffmann, P., Warner, B. (2006) Are hERG channel inhibition and QT prolongation all there is in drug-induced torsadogenesis? A review of emerging trends *Journal of Pharmacological and Toxicological Methods* **53**, 87-105
10. Arrigoni, C., Crivori, P. (2007) Assessment of QT liabilities in drug development *Cell and Biological Toxicology* **23**, 1-13
11. ICH Topic S7A: Safety pharmacology studies for human pharmaceuticals CPMP/ICH/539/00; ICH Topic S7B: The nonclinical Evaluation of the Potential for delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals CPMP/ICH/423/02; ICH Topic E14: the Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs CHMP/ICH/2/04
12. ICH Topic S2A: Guidance on Specific Aspects of Regulatory Genotoxicity Testes for Pharmaceuticals; ICH Topic S2B: Genotoxicity: A Standard Battery for Genotoxicity Testing of Pharmaceuticals
13. Ashby, J. (1985) Fundamental structural alerts to potential carcinogenicity or noncarcinogenicity. *Environmental Mutagenesis* **7**, 919-922
14. Ashby, J., Tennant R.W. (1991) Definitive relationships among chemical structure, carcinogenicity and mutagenicity for 301 chemicals tested by the US NTP. *Mutation Research* **257**, 229-306
15. Kazius, J., McGuire, R., Bursi, R. (2005) Derivation and validation of toxicophores for mutagenicity prediction. *Journal of Medicinal Chemistry* **48**, 312-320
16. Benigni, R. (2005) Structure-activity relationship studies of chemical mutagens and carcinogens: Mechanistic investigation and prediction approaches. *Chemical Reviews* **105**, 1767-1800
17. Klopman, G. (1992) Multi-CASE: A hierarchical computer automated structure evaluation program *QSAR II*, 172-184
18. Judson, P.N. (1994). Rule Induction for Systems Predicting Biological Activity. *Journal of Chemical Information and Computer Sciences* **34**, 148-153
19. Hatch, F.T., Knize, M.G., Colvin, M.E. (2001) Extended quantitative structure-activity relationships for 80 aromatic and heterocyclic amines: Structural, electronic, hydrophobic factors affecting mutagenic potency. *Environmental and Molecular Mutagenesis* **38**, 268-291
20. Kirkland, D., Aardema, M., Henderson, L., Müller, L. (2005) Evaluation of the ability of a battery of three in vitro genotoxicity tests to discriminate rodent carcinogens and non-carcinogens I. Sensitivity, specificity and relative predictivity *Mutation Research* **584**, 1-256
21. Baillie, T.A., Kassahun, K. (2001) Biological reactive intermediates in drug discovery and development: a perspective from the pharmaceutical industry. *Advance in Experimental Medicine and Biology* **500**, 45-51
22. Dambach, D.M., Andrews, B.A., Moulin, F. (2005) New technologies and screening strategies for hepatotoxicity: Use of in vitro models. *Toxicologic Pathology* **33**, 17-26
23. <http://chem.sis.nlm.nih.gov/chemidplus>
24. <http://ecb.jrc.it/iuclid>
25. <http://toxnet.nlm.nih.gov>
26. <http://www.epa.gov/ncct/dssto>
27. <http://www.multicase.com>
28. <http://www.lhasalimited.org>
29. http://www.gvkbio.com/database_pdf/Mechanism_Based_Toxicity.pdf
30. Bhogal, N., Grindon, C., Combes, R., Balls, M. (2005) Toxicity testing: creating a revolution based on new technologies. *TRENDS in Biotechnology* **23**, 299-307
31. Lang, P., Yeow, K., Nichols, A., Scheer, A. (2006) Cellular imaging in Drug Discovery. *Nature Reviews Drug Discovery* **5**, 343-356
32. Hamadeh, H.K., Amin, R.P., Paules, R.S., Afshari, C.A. (2002) An overview of toxicogenomics. *Current Issues in Molecular Biology* **4**, 45-56
33. Hayes, K.R., Bradfield, C.A. (2005) Advances in toxicogenomics. *Chemical Research in Toxicology* **18**, 404-414


Top Quality Bioscience Journals



Molecular BioSystems is a high quality chemical biology journal with a focus on the interface between chemistry and the -omic sciences and systems biology.

Impact factor: 2.45*

www.molecularbiosystems.org



Organic & Biomolecular Chemistry is an international journal for the quickest publication of high-quality research covering the breadth of synthetic, physical and biomolecular chemistry

Impact factor: 2.874*

www.rsc.org/obc



National Product Reports (NPR) is a critical review journal which stimulates progress in all areas of natural products research.

Impact factor: 8.89*

www.rsc.org/npr



Photochemical & Photobiological Sciences is a photoscience journal with rapid publication times and the highest impact factor in its field.

Impact factor: 2.416*

www.rsc.org/pps

Submit your work today!

*2006 Thompson Scientific (ISI) Journal Citation Reports

RSC Publishing

www.rsc.org/journals

Registered Charity Number 207890

RSC Biomolecular Sciences Series

The RSC Biomolecular Sciences Series is devoted to the coverage of the interface between the chemical and biological sciences, especially structural biology, chemical biology, bio- and chemo-informatics, drug discovery and development, chemical enzymology and biophysical chemistry. The books are ideal as a reference and state-of-the-art guides at the graduate and postgraduate levels.



Structure-Based Drug Discovery: An Overview

Edited by *R E Hubbard*

"There are very few of us who will invent a drug, but by using the techniques described (in this book), you will shorten your own odds considerably."

Reviewed in *Chemistry World*

2006 | xvi+262 pages | 978 0 85404 351 4 | £74.95



Exploiting Chemical Diversity for Drug Discovery

Edited by *P A Bartlett and M Entzeroth*

"...is an excellent and astonishingly complete compilation on this broad and demanding topic for current practitioners."

Reviewed in *Angewandte Chemie*

2006 | xxiv+420 pages | 978 0 85404 842 7 | £119.95



Sequence-specific DNA Binding Agents

Edited by *M Waring*

"An excellent overview of the work being done in the exciting areas of discovering agents that exhibit selectivity and sequence specificity for DNA."

Reviewed in *ChemBioChem*

2006 | xii+258 pages | 978 0 85404 370 5 | £79.95

Forthcoming Winter 2007

Metabolomics, Metabonomics and Metabolite Profiling

Edited by: *W Griffiths*

ISBN: 978085404299

Price: £89.00

Computational and Structural Approaches to Drug Discovery

Edited by: *R Stroud and J Finer-Moore*

ISBN: 9780854043651

Price: £89.00

Ribozymes and RNA Catalysis

Edited by: *D M J Lilley and F Eckstein*

ISBN: 9780854042531

Price: £79.95

RSC Publishing

www.rsc.org/books

Registered Charity Number: 207090



Current Drug Metabolism

(J.F. 5.78)

"Current Drug Metabolism represents an important review journal of great value to pharmaceutical scientists."

(Donald Everett
Bristol-Myers Squibb, USA)

Volume 8, 8 Issues, 2007
Personal Subscription: \$ 380.00

Current Drug Targets

(J.F. 4.37)

"In view of the growing volume of literature, the role of high quality review journals has become increasingly important. Current Drug Targets is an important journal in the field of medicinal chemistry and drug design, which is strongly recommended to the scientific community."

(Jean-Marie Lehn
Nobel Laureate)

Volume 8, 12 Issues, 2007
Personal Subscription: \$ 450.00

Mini-Reviews in Medicinal Chemistry

(J.F. 3.16)

"Mini-Reviews in Medicinal Chemistry represents an important review journal of great value to pharmaceutical scientists."

(Jean-Marie Lehn
Nobel Laureate)

Volume 7, 12 Issues, 2007
Personal Subscription: \$ 450.00

The Essential Journal Collection

Current Cancer Drug Targets

(J.F. 5.67)

Answering the information needs of the rapidly evolving field of cancer drug targets, the journal publishes timely, in-depth reviews, covering a range of current topics within the field.

Volume 7, 8 Issues, 2007
Personal Subscription: \$ 300.00

Combinatorial Chemistry & High Throughput Screening

(J.F. 2.55)

"Combinatorial Chemistry & High Throughput Screening is a pivotal journal in the field of drug discovery."

(Norman R. Farnsworth
University of Illinois at Chicago, USA)

Volume 10, 10 Issues, 2007
Personal Subscription: \$ 330.00

Current Organic Chemistry

(J.F. 3.23)

"Current Organic Chemistry is an important review journal, which should prove to be of wide interest to organic chemists and provide them with a convenient means of keeping up with the current flood of advances in the field."

(H.C. Brown
Nobel Laureate)

Volume 11, 18 Issues, 2007
Personal Subscription: \$ 510.00

Current Pharmaceutical Design

(J.F. 3.27)

"This journal is a necessity for scientists working in the multidisciplinary fields encompassing the areas of drug design and discovery."

(Annette M. Doherty
Pfizer Global R&D, France)

Volume 13, 36 Issues, 2007
Personal Subscription: \$ 1,170.00

Current Topics in Medicinal Chemistry

(J.F. 4.18)

"Current Topics in Medicinal Chemistry provides medicinal chemists and scientists in allied disciplines an invaluable resource for thematic coverage of keen new developments in their field of study."

(Sir James Black
Nobel Laureate)

Volume 7, 18 Issues, 2007
Personal Subscription: \$ 440.00

Current Molecular Medicine

(J.F. 4.85)

"A critically important journal that fills an important niche."

(David Weiner
Pennsylvania School of Medicine,

Volume 7, 8 Issues, 2007
Personal Subscription: \$ 380.00

Current Medicinal Chemistry

(J.F. 5.26)

"Current Medicinal Chemistry has established itself as an important review journal in the field of medicinal chemistry. The journal is highly recommended to all scientists active in the field of medicinal chemistry."

(Richard R. Ernst
Nobel Laureate)

Volume 14, 30 Issues, 2007
Personal Subscription: \$ 800.00

Get your FREE copy online now!

www.bentham.org

For Information or to Subscribe:

subscriptions@bentham.org

Tel: +971 65571132; Fax: +971 66571134



**BENTHAM
SCIENCE**

ADHERING ORGANISATIONS

AUSTRIA	Austrian Chemical Society, Medicinal Chemistry Section
BELGIUM	Medicinal and Bioorganic Chemistry Division of Royal Flemish Chemical Society (KVCV) Société Royale de Chimie (SRC), Medicinal Chemistry Division
DENMARK	The Danish Society for Pharmacology and Toxicology
FRANCE	Société de Chimie Thérapeutique
GERMANY	Division of Medicinal Chemistry of the German Chemical Society (GDCh) German Pharmaceutical Society, Section of Pharmaceutical/Medicinal chemistry
GREECE	Hellenic Society of Medicinal Chemistry
HUNGARY	Organic and Medicinal Chemistry Division (OMCD) of the Hungarian Chemical Society (HCS)
ISRAËL	The Medicinal Chemistry Section of the Israel Chemical Society
ITALY	Division of Medicinal Chemistry of the Italian Chemical Society (Società Chimica Italiana)
LATVIA	Latvian Association for Medicinal Chemistry
POLAND	Polish Society of Medicinal Chemistry
PORTUGAL	Group of Medicinal Chemistry of the Portuguese Chemical Society
RUSSIA	The D.I. Mendeleev Russian Chemical Society, Medicinal Chemistry Section
SLOVENIA	Section for Medicinal Chemistry of the Slovenian Pharmaceutical Society
SPAIN	Sociedad Española de Química Terapéutica
SWEDEN	The Swedish Academy of Pharmaceutical Sciences
SWITZERLAND	Division for Medicinal Chemistry (DMC), Swiss Chemical Society (SCS)
THE NETHERLANDS	Section of Pharmacochimistry, Royal Netherlands Chemical Society (KNCV)
TURKEY	Turkish Association of Medicinal and Pharmaceutical Chemistry
UNITED KINGDOM	The Biological and Medicinal Chemistry Sector (BMCS) of the Royal Society of Chemistry (RSC) Society for Medicines Research



AUSTRIAN CHEMICAL SOCIETY, MEDICINAL CHEMISTRY SECTION

To foster medicinal chemistry in Austria by jointly organising and hosting national and international summerschools, minisymposia and workshops together with the Austrian Pharmaceutical Society.

1999

100

Trade and Industry: 27%
Research Institute and University: 46%
Others: 27%

Nibelungengasse 11/6
AT-1010 Vienna Austria

+43 1 587 42 49 or +43 1 587 39 80
+43 1 587 89 66

office@goech.at
www.goech.at

XXth International Symposium on Medicinal Chemistry •
(August 31 - September 4, 2008), Vienna, Austria

Prof. Marko MIHOVILOVIC
(TU VIENNA)

Mrs Gabriela EBNER
(AUSTRIAN CHEMICAL SOCIETY)

Dr. Peter ETTMAYER
(BOEHRINGER INGELHEIM AUSTRIA GmbH)

MISSION

FOUNDED
MEMBERS

MEMBER PROFILE

POSTAL ADDRESS

TELEPHONE
FAXE-MAIL
WEBSITE

ACTIVITIES

PRESIDENT

SECRETARY

EFMC-DELEGATE

MEDICINAL AND BIOORGANIC CHEMISTRY DIVISION OF ROYAL FLEMISH CHEMICAL SOCIETY (KVCV)



MISSION	Organisation of symposia and activities. Promotion of contacts between industry and academia Promotion of contacts with other national and international organisations.
FOUNDED	2002
MEMBERS	120
POSTAL ADDRESS	Celestijnenlaan 200F BE-3001 Herverlee Belgium
TELEPHONE	+32 16 29 32 14
FAX	+32 16 22 68 92
E-MAIL	info@kvcv.be
WEBSITE	www.kvcv.be
ACTIVITIES	<p>Every 2 years the J&J PRD award for Medicinal Chemistry is given to an outstanding Ph.D. thesis in the field</p> <ul style="list-style-type: none"> • Annual One Day Meeting on Medicinal Chemistry (October 2008) • XXIst International Symposium on Medicinal Chemistry (August 2010), Brussels, Belgium
PRESIDENT	Prof. Koen AUGUSTYNS (UNIVERSITEIT ANTWERPEN)
SECRETARY	Dr. Peter TEN HOLTE (J&J PRD)
EFMC-DELEGATE	Prof. Koen AUGUSTYNS (UNIVERSITEIT ANTWERPEN)

SOLVAY



Passion for progress, care for people

We want to apply genuine innovation in carefully chosen areas in order to meet as yet unfulfilled medical needs. Pioneering research is needed for this. We conduct this research with great passion, commitment and resolve.

After all, we are talking about the health of human beings. This demonstrates the responsibility of Solvay Pharmaceuticals as an international pharmaceutical company for the world in which we live.

Solvay Pharmaceuticals B.V.
P.O. Box 900, 1380 DA Woosd
The Netherlands
Telephone +31 (0)294 47 70 00
www.solvaypharmaceuticals.com

Solvay
Pharmaceuticals



a Passion for Progress®

Chemical and pharmaceutical group

SOCIÉTÉ ROYALE DE CHIMIE (SRC),
Medicinal Chemistry Division



MISSION	The Division of Medicinal Chemistry of the SRC provides a forum for scientists interested in medicinal chemistry and related areas in pharmaceutical research. The Division's activities intend to bring together its members and to foster contacts in a European context.
FOUNDED	1973
MEMBERS	120
POSTAL ADDRESS	ULB, CP 160/07 Avenue F. Roosevelt, 50 BE-1050 Bruxelles Belgium
TELEPHONE	+32 2 650 52 08
FAX	+32 2 650 51 84
E-MAIL	src@ulb.ac.be
WEBSITE	www.src.be
ACTIVITIES	<p>The DMC confers, every 2 years, the «Johnson and Johnson Pharmaceutical Research and Development Award for Young Medicinal Chemists» to acknowledge an outstanding Ph.D. thesis work.</p> <p>The DMC organises annually a Symposium aimed at updating interested participants on particularly rapidly evolving areas of pharmaceutical research, by specialists in their respective field.</p> <ul style="list-style-type: none"> • Annual One Day Meeting on Medicinal Chemistry (October 2008). • XX1st International Symposium on Medicinal Chemistry (August 2010), Brussels, Belgium
PRESIDENT	Dr. Edmond DIFFERDING (UCB)
EFMC-DELEGATE	Dr. Edmond DIFFERDING (UCB)



THE DANISH SOCIETY FOR PHARMACOLOGY AND TOXICOLOGY

To advance the development of pharmacology, toxicology
and medicinal chemistry.

377 members of which 120 are members
of the medicinal chemistry section.

Trade and Industry: 50%
Research Institute and University: 50%

Att. Inger Marie Bro
Wilh. Meyers Alle, bygning 240
Bartholinbygningen, Univ.park
DK - 8000 Århus C Denmark

+45 89 42 17 26
+45 86 12 88 04

imb@farm.au.dk
www.dsft.dk

5-10 yearly seminars on current topics in pharmacology,
toxicology and medicinal chemistry.

Danish Pharmacology 2008 •
(January 16, 2008), Odense, Denmark
Annual Meeting - « Early Drug Discovery » •
(May 15-16, 2008), Copenhagen, Denmark

Prof. Ulf SIMONSEN
(UNIVERSITY OF AARHUS)
Assoc. Prof. Mette M. ROSENKILDE
(UNIVERSITY OF COPENHAGEN)
Prof. Kristian STRØMGAARD
(UNIVERSITY OF COPENHAGEN)

MISSION

MEMBERS

MEMBER PROFILE

POSTAL ADDRESS

TELEPHONE FAX

E-MAIL WEBSITE

ACTIVITIES

PRESIDENT

SECRETARY

EFMC-DELEGATE

SOCIÉTÉ DE CHIMIE THÉRAPEUTIQUE



MISSION	To gather medicinal chemists in order to promote progress in Medicinal Chemistry by organising meetings, distributing awards and grants, encouraging junior scientists and publishing medicinal chemistry journals or series.
FOUNDED	1966
MEMBERS	302
MEMBER PROFILE	Trade and Industry: 17% Research Institute: 8% University: 70% Other: 5%
POSTAL ADDRESS	5, rue Jean-Baptiste Clément FR-92296 Chatenay-Malabry France
TELEPHONE	+33 1 46 83 56 84
FAX	+33 1 46 83 53 23
E-MAIL	herve.galons@univ-paris5.fr
WEBSITE	www.sct.asso.fr
ACTIVITIES	<p>Organisation of meetings and conferences.</p> <p>AWARDS:</p> <p>Every two-year: <i>Prix Charles Mentzer</i>, rewarding a fruitful career in Medicinal Chemistry. Every year: <i>Prix d'encouragement à la recherche en Chimie Thérapeutique</i>, for junior scientists. <i>Paul Ehrlich Lecture</i>, attributed during the annual meeting. <i>Prix de la vocation en Chimie Thérapeutique</i>, attributed to students during the annual meeting.</p> <p>PUBLISHING ACTIVITIES:</p> <p>Scientific editing of The European Journal of Medicinal Chemistry, Elsevier, 1 issue per month (2004 Volume 39). Actualités de Chimie Thérapeutique, 1 volume per year (2004 n° 30).</p> <ul style="list-style-type: none"> • Young Research Fellows Meeting (January 31, 2008), Paris, France • Joint Meeting SCT - SFC - Académie de Pharmacie (March 11, 2008), Paris, France • RICT 44 - Rencontres Internationales de Chimie Thérapeutique. International Conference in Medicinal Chemistry: Interfacing Chemical Biology, Natural Products and Drug Discovery (July 2-4, 2008), Angers, France • SCT Annual Workshop in Medicinal Chemistry (December 2008), Paris, France
PRESIDENT	Dr. Yves ROLLAND (SERVIER)
SECRETARY	Prof. Hervé GALONS (UNIVERSITÉ PARIS V)
EFMC-DELEGATE	Prof. Olivier LAFONT (FACULTÉ DE MÉDECINE ET DE PHARMACIE DE ROUEN)

Value through Innovation



**With R&D spending of more than €1.4 billion a year,
we're always seeking talent and ideas. Maybe yours?**

Boehringer Ingelheim equates success as a pharmaceutical company with developing therapies that make a difference. R&D is our driving force. Our scientific teams strictly focus on innovation, with a devotion to excellence. We collaborate with academic institutions and businesses around the world, transforming good ideas into outstanding products. All this creates a global community of innovators dedicated to improving human health.

www.boehringer-ingelheim.com

Interested? Then contact us:
www.boehringer-ingelheim.com, click on careers for job applications
licensing@ing.boehringer-ingelheim.com for partnering opportunities



DIVISION OF MEDICINAL CHEMISTRY OF THE GERMAN CHEMICAL SOCIETY (GDCh)



MISSION	To foster the whole area of Medicinal Chemistry in University and Pharmaceutical Industry. The Division builds an interdisciplinary bridge between Chemistry, Biology, Medicine and Pharmacy.
FOUNDED	1971 at Karlsruhe, Germany
MEMBERS	650
MEMBER PROFILE	Trade and Industry: 60% Research Institute and University: 35% Other: 5%
POSTAL ADDRESS	Varrentrappstr. 40-42 DE-60486 Frankfurt am Main Germany
TELEPHONE	+49 69 7917 363
FAX	+49 69 7917 450
E-MAIL	U.Bechler@gdch.de
WEBSITE	www.gdch.de/medchem
ACTIVITIES	Annual meetings, interdisciplinary symposia, scientific publications, award. <ul style="list-style-type: none"> Frontiers in Medicinal Chemistry (March 2-5, 2008), Regensburg, Germany
PRESIDENT	Dr. Hans-Ulrich STILZ (AVENTIS PHARMA DEUTSCHLAND GmbH)
EFMC-DELEGATE	Prof. Dr. Gerd SCHNORRENBURG (BOEHRINGER INGELHEIM PHARMA KG)



**GERMAN PHARMACEUTICAL SOCIETY,
SECTION OF PHARMACEUTICAL/MEDICINAL CHEMISTRY**

To foster the whole area of Medicinal Chemistry in University and Pharmaceutical Industry by annual meetings, awards and activities related to the education in Medicinal Chemistry.

1985
679

Trade and Industry: 20%
University: 60%
Others: 20%

Hamburger Allee 26-28
DE-60486 Frankfurt am Main Germany

+49 69 7917 555
+49 69 7917 553

info@dphg.de
www.dphg.de

Annual awards in Medicinal Chemistry (Germany),
cooperations with other organisations, support of the
education in Medicinal Chemistry, annual meetings.

Frontiers in Medicinal Chemistry •
(March 2-5, 2008), Regensburg, Germany

Prof. Dr. Bernd CLEMENT
(UNIVERSITÄT KIEL)

MISSION

**FOUNDED
MEMBERS**

MEMBER PROFILE

POSTAL ADDRESS

**TELEPHONE
FAX**

**E-MAIL
WEBSITE**

ACTIVITIES

PRESIDENT

HELLENIC SOCIETY OF MEDICINAL CHEMISTRY



MISSION	Advancement of research in Medicinal Chemistry and Drug Design, promotion of cooperation between scientists of related fields and consulting on relevant subjects.
FOUNDED	1980
MEMBERS	107
MEMBER PROFILE	Trade and Industry: 20% Research Institute: 30% University: 40% Other: 10%
POSTAL ADDRESS	School of Pharmacy , Department of Pharmaceutical Chemistry, University of Athens, Greece Panepistimiopolis, Zografou GR-157 71 Athens Greece
TELEPHONE	+30 210 7274 530
FAX	+30 210 7274 747
E-MAIL	tsantili@pharm.uoa.gr , snikolar@upatras.gr
ACTIVITIES	Symposia, seminars, consulting. <ul style="list-style-type: none"> 13th Panhellenic Symposium on Medicinal Chemistry (March 14-15, 2008), Athens, Greece
PRESIDENT	Assoc. Prof. Dr. Anna TSANTILI-KAKOULIDOU (UNIVERSITY OF ATHENS)
SECRETARY/TREASURER	Assist Prof. Dr. Sotiris NIKOLAROPOULOS / Dr. Ioanna ANDREADOU (UNIVERSITY OF PATRAS / UNIVERSITY OF ATHENS)
EFMC-DELEGATE	Assoc Prof. Anna TSANTILI-KAKOULIDOU (UNIVERSITY OF ATHENS)



ORGANIC AND MEDICINAL CHEMISTRY DIVISION (OMCD) OF THE HUNGARIAN CHEMICAL SOCIETY (HCS)

The dissemination of results and particularly of new trends in organic and medicinal chemistry among Hungarian scientists.

1907 (HCS)
300 (Medicinal Chemistry oriented members of the OMCD)

Trade and Industry: 40%
Research Institute: 20%
University: 30%
Others: 10%

Fo u. 68
HU-1027 Budapest Hűngary

+36 1 201 6883
+36 1 201 8056
mail@mke.org.hu
www.mke.org.hu

Regular organisation of conferences, seminars and lectures in various fields of medicinal chemistry. Encouragement and initiating the development of new generations of scientists working in this field. Bimonthly seminars by invited scientists in the field of medicinal chemistry.

- International Symposium on the Industrial Applications •
of the Mössbauer Effect
(August 17-22, 2008), Budapest, Hungary
- Seventh International Conference on Nuclear and Radiochemistry •
(August 24-29, 2008), Budapest, Hungary
- Metabolic Disorders - from Bench to Bedside •
(August 28-31, 2008), Sopron, Hungary
- International Conference on Metrology of Environmental
Food and Nutritional Measurements
(September 9-12, 2008), Budapest, Hungary
- INTERFACES '08 •
(September 24-26, 2008), Sopron, Hungary

Prof. Dr. Péter MÁTYUS (SEMELWEIS UNIVERSITY)
Dr. János WÖLFLING (UNIVERSITY OF SZEGED)
Dr. János WÖLFLING (UNIVERSITY OF SZEGED)

MISSION

FOUNDED MEMBERS

MEMBER PROFILE

POSTAL ADDRESS

TELEPHONE FAX E-MAIL WEBSITE

ACTIVITIES

PRESIDENT SECRETARY EFMC-DELEGATE

THE MEDICINAL CHEMISTRY SECTION OF THE ISRAEL CHEMICAL SOCIETY



MISSION	To organise and to foster the interaction between medicinal chemists in academia, industry and drug dispensing institutions, in an independent Association devoted to education, research and development of Medicinal Chemistry through meetings and workshops, and to represent the Association at the national level, at the EFMC, and at related international levels. IAMC is open for membership to molecular biologists, pharmacologists and pharmacists.
FOUNDED	1991 2004 united with the Israel Association for Medicinal Chemistry
MEMBERS MEMBER PROFILE	200 Trade and Industry: 35% Research Institute and University: 60% Other: 5%
POSTAL ADDRESS	Department of Medicinal Chemistry and Natural Products School of Pharmacy – Faculty of Medicine Hebrew University of Jerusalem PO Box 12065 IL-91120 Jerusalem, Israel
TELEPHONE	+972 2675 75 73, cell: +972 52 4282677
FAX	+972 2675 70 76
E-MAIL	avid@ekmd.huji.ac.il
WEBSITE	www.weizmann.ac.il/conferences/medchem/
ACTIVITIES	The Association holds symposia and annual scientific meetings. Promotion of one-day symposia on new vistas in drug research and a workshop on progress in instrumental drug analysis, and representation of the Association at the EFMC and related international bodies.
PRESIDENT	Prof. Abraham DOMB J. (HEBREW UNIVERSITY OF JERUSALEM)
EFMC-DELEGATE	Dr. Jeffrey STERLING (TEVA PHARMACEUTICAL Ind.)



DIVISION OF MEDICINAL CHEMISTRY OF THE ITALIAN CHEMICAL SOCIETY (Società Chimica Italiana)

To improve Medicinal Chemistry in academia and industry by promoting contacts and collaboration between researchers working in this and related fields with the aim to propose and develop projects to advance Medicinal Chemistry; to organise national and international meetings, interdisciplinary symposia and advanced schools to spread the knowledge in drug development; to distribute awards and grants that encourage junior scientists to pursue research in Medicinal Chemistry; to cooperate with similar associations in the country and abroad.

1979
578

Trade and Industry: 13%
Research Institute: 0.5%
University: 86%
Other: 0.5%

Divisione di Chimica Farmaceutica
University of Genova-Dipartimento di Scienze Farmaceutiche
Viale Benedetto XV, 3
IT-16132 Genova Italy
+ 39 010 353 8350
+ 39 010 353 8358
mosti@unige.it
dcf.frm.uniroma1.it/cgi-bin/home.pl

28th Edition of the European School of Medicinal Chemistry (ESMEC) •
(July 6-11, 2008), Urbino, Italy
XIXth National Meeting on Medicinal Chemistry •
(September 14-18, 2008), Verona, Italy

Prof. Luisa MOSTI
(UNIVERSITY OF GENOVA)
Prof. Dr. Antonello MAI
(UNIVERSITY DI ROMA «LA SAPIENZA»)
Prof. Carlo FRANCHINI
(UNIVERSITY OF BARI)
Prof. Luisa MOSTI
(UNIVERSITY OF GENOVA)

MISSION

FOUNDED MEMBERS

MEMBER PROFILE

POSTAL ADDRESS

TELEPHONE
FAX
E-MAIL
WEBSITE

ACTIVITIES

PRESIDENT

SECRETARY

TREASURER

EFMC-DELEGATE

FOUNDED	1992
MEMBERS	12
MEMBER PROFILE	Research Institute and University: 83% Other: 17%
POSTAL ADDRESS	Latvian University Institute of Microbiology and Biotechnology 4-402 Kronvalda Boulevard LV-1586 Riga Latvia
TELEPHONE	+371 7034890
FAX	+371 7323065
E-MAIL	vina@lanet.lv
ACTIVITIES	Promotion of medicinal chemistry
PRESIDENT	Dr. Ilmara VINA (LATVIAN UNIVERSITY)
EFMC-DELEGATE	Prof. Dr. Gunars DUBURS (LATVIAN INSTITUTE OF ORGANIC SYNTHESIS)



POLISH SOCIETY OF MEDICINAL CHEMISTRY

Basis for mutual contacts and integration for scientists who represent different profile of their activity in the following areas of medicinal chemistry: organic and bioorganic synthesis, analytical chemistry, computational chemistry, biochemistry, molecular biology, biotechnology, pharmacy and medicine.

2006

50

Jagiellonian University
Medical College, Pharmacy Faculty
Medyczna 9
PL - 30-688 Kraków Poland

+48 12 657 04 88

+48 12 657 04 88

mfkonono@cyf-kr.edu.pl
www.ptchem.lodz.pl/en

- Organization of occasional gatherings where various theoretical and practical topics of drug research and development are discussed
- Participation in organization of national and international conferences on medicinal chemistry
- Organization of the platform for exchange of ideas, news and informations on medicinal chemistry activities in the scientific society interested in this broad subject

Prof. Janina KAROLAK-WOJCIECHOWSKA
Prof. Dariusz MATOSIUK
Prof. Katarzyna KIEĆ-KONONOWICZ
(JAGIELLONIAN UNIVERSITY)
Prof. Katarzyna KIEĆ-KONONOWICZ

MISSION

FOUNDED MEMBERS

POSTAL ADDRESS

TELEPHONE FAX

E-MAIL WEBSITE

ACTIVITIES

PRESIDENT VICE-PRESIDENT EFMC-DELEGATE

EFMC-CORRESPONDENT

GROUP OF MEDICINAL CHEMISTRY OF THE PORTUGUESE CHEMICAL SOCIETY



MISSION	<ul style="list-style-type: none"> - To diffuse the knowledge of Medicinal Chemistry. - To foster interdisciplinary bridges between Chemistry, Biology, Medicine and Pharmacy. - To encourage research among young students. - To promote the interaction between medicinal chemists in academia and professionals in industry.
FOUNDED	2007
MEMBERS	62
POSTAL ADDRESS	<p>Sociedade Portuguesa de Química Av. da República, 37-40 PT-1050 187 Lisboa Portugal</p>
TELEPHONE	+351 21 793 4637
FAX	+351 21 795 2349
E-MAIL	sede@spq.pt
WEBSITE	www.spq.pt
ACTIVITIES	<p>Promotion of activities to reach a high experience and development in Medicinal Chemistry and to push every boundary to integrate education and research in the area.</p> <p>Organisation of meetings, advanced courses and seminars in different areas of Medicinal Chemistry.</p> <p>A National Meeting in Medicinal Chemistry is planned for December 2008.</p>
PRESIDENT	<p>Prof. M. Luisa SÁ E MELO (UNIVERSITY OF COIMBRA)</p>
EFMC-DELEGATE	<p>Prof. Rui MOREIRA (UNIVERSITY OF LISBON)</p>



THE D.I. MENDELEEV RUSSIAN CHEMICAL SOCIETY MEDICINAL CHEMISTRY SECTION

Education in medicinal chemistry.
Organisation of regular scientific seminars.

2000

150

Research Institute: 67%

University: 26%

Other: 7%

RU-119899 Moscow Russia

+ 7 095 939 1620

+ 7 095 939 0290

zefirov@org.chem.msu.ru

Organising regular and specific seminars in medicinal chemistry.
Assisting in the organisation of regular courses for undergraduate students of Moscow State University in medicinal chemistry.
Providing interaction between Russian academician research in the field of medicinal chemistry and industrial institutions.

Prof. Dr. Nikolay S. ZEFIROV
(MOSCOW STATE UNIVERSITY)

Prof. Dr. Nikolay S. ZEFIROV
(MOSCOW STATE UNIVERSITY)

MISSION

FOUNDED MEMBERS

MEMBER PROFILE

POSTAL ADDRESS

TELEPHONE FAX

E-MAIL

ACTIVITIES

PRESIDENT

EFMC-DELEGATE

SECTION FOR MEDICINAL CHEMISTRY OF THE SLOVENIAN PHARMACEUTICAL SOCIETY



MISSION	The mission of the Section for Medicinal Chemistry of the Slovenian society is the advancement and promotion of medicinal chemistry in Slovenia and Europe. It will pursue its mission by organising scientific meetings, schools and working-group in order to encourage discussions and exchange of ideas in the field of medicinal chemistry. This section will cooperate with similar associations in the country and abroad.
FOUNDED	23 February 2004
MEMBERS	28
MEMBER PROFILE	Trade and Industry: 20 % Research Institute: 15 % University: 60 % Others: 5 %
POSTAL ADDRESS	University of Ljubljana, Faculty of Pharmacy Aškerceva 7 SI- 1000 Ljubljana Slovenia
TELEPHONE	+386 1 4769561
FAX	+386 1 4258031
E-MAIL	danijel.kikelj@ffa.uni-lj.si
WEBSITE	www.farmacevtsko-drustvo.si
PRESIDENT	Dr. Lucija PETERLIN MAŠIĆ (UNIVERSITY OF LJUBLJANA)
EFMC-DELEGATE	Prof. Danijel KIKELJ (UNIVERSITY OF LJUBLJANA)



SOCIEDAD ESPAÑOLA DE QUÍMICA TERAPÉUTICA

To assist in the development and improvement of research and training in the different areas of Medicinal Chemistry throughout Spain.

MISSION

1977

FOUNDED

375

MEMBERS

Trade & Industry: 25%

Research Institute: 30%

University: 35%

Other: 10%

MEMBER PROFILE

SEQT

Juan de la Cierva,3

ES-28006 Madrid Spain

POSTAL ADDRESS

+34 91 56 22 900

+34 91 56 44 853

TELEPHONE

FAX

seqt@iqm.csic.es

www.seqt.org

E-MAIL

WEBSITE

Supporting the participation of young researchers at meetings and other educational events. Organising symposia on topics related with research and education towards the discovery of new drugs.

Sponsoring the Spanish Society of Medicinal Chemistry Award.

Administrating five Awards addressed to young scientists to acknowledge outstanding research in the field of Medicinal Chemistry.

ACTIVITIES

VIII Jornadas de la SEQT •
(October 2008), Carmona - Sevilla, Spain

Dr. María L. LÓPEZ-RODRÍGUEZ
(UNIVERSIDAD COMPLUTENSE DE MADRID)

PRESIDENT

Dr. Ana Rosa SAN FÉLIX GARCÍA
(IQM-CSIC)

SECRETARY

Dr. Sonsoles VELÁZQUEZ DÍAZ
(IQM-CSIC)

TREASURER

Dr. Marina GORDALIZA-ESCOBAR
(UNIVERSIDAD DE SALAMANCA)

EFMC-DELEGATE



PROUS SCIENCE

Integrity®

Empowering knowledge-based drug discovery and development

The preferred drug R&D portal where knowledge areas are coordinated to provide a harmonious, interrelated whole.

Knowledge Areas include:

Drugs & Biologics, Targets & Pathways, Genomics, Biomarkers, Organic Synthesis, Experimental Pharmacology, Pharmacokinetics and Metabolism, Clinical Studies, Disease Briefings, Companies & Research Institutions, Literature and Patents.

To learn how Integrity® and other Prous Science products can empower your drug R&D activities, point your browser to www.prous.com

<http://integrity.prous.com>

To strengthen the Medicinal Chemistry Discipline through the arrangement of conferences, seminars and other educational initiatives.

1972

276

Trade & Industry: 70%

Research Institute: 1%

University: 19%

Other: 10%

Wallingatan 26A
 SE-111 81 Stockholm Sweden

+46 8 723 50 00

+46 8 20 55 11

goran.lidgren@lakemedelsakademin.se
www.swepharm.se

Symposia, seminars, courses.

Activities for 2008 will come up soon!
 4th Anglo-Swedish Medicinal Chemistry Symposium •
 (March 2009), Åre, Sweden

Dr. Anders KARLÉN
 (UPPSALA UNIVERSITY)
 Anna-Lena GUSTAVSSON
 (BIOVITRUM)

Dr. Anders KARLÉN
 (UPPSALA UNIVERSITY)

MISSION

FOUNDED MEMBERS

MEMBER PROFILE

POSTAL ADDRESS

TELEPHONE FAX

E-MAIL WEBSITE

ACTIVITIES

PRESIDENT

SECRETARY/TREASURER

EFMC-DELEGATE

DIVISION FOR MEDICINAL CHEMISTRY (DMC), SWISS CHEMICAL SOCIETY (SCS)



MISSION	The DMC provides a forum for scientists interested in medicinal chemistry and related fields by organising symposia, seminars, presentations and courses.
FOUNDED	1990
MEMBERS	605
MEMBER PROFILE	Trade & Industry: 78% Research Institute: 3% University: 11% Other: 8%
POSTAL ADDRESS	Schwarztorstrasse 9 CH-3007 Bern Switzerland
TELEPHONE	+41 31 310 40 90
FAX	+41 31 310 40 29
E-MAIL	info@scg.ch
WEBSITE	www.scg.ch
ACTIVITIES	<ul style="list-style-type: none"> • Minisymposium on «Drug Targeting» (May 29, 2008), Basel, Switzerland • Fall Meeting of the Swiss Chemical Society (September 11, 2008), Zürich, Switzerland • 8th Swiss Course on Medicinal Chemistry (October 12-17, 2008), Leysin, Switzerland
PRESIDENT	Dr. Hans Peter MAERKI (HOFFMANN-LA ROCHE AG)
EFMC-DELEGATE	Dr. Peter MOHR (HOFFMANN-LA ROCHE AG)



SECTION OF PHARMACOCHEMISTRY, ROYAL NETHERLANDS CHEMICAL SOCIETY (KNCV)

To promote scientific research and education in the area of pharmacocchemistry. To bring together scientists in the field and to offer them a platform for discussion and exchange of ideas. To identify talent in the field. To organise meetings in the field.

28th August 1970
400 (including student members)
Trade & Industry: 20%
Research Institute: 10%
University: 40%
Other: 30%

Dr. J.C.H.M. Wijkmans
N.V. Organon
Department of Medicinal Chemistry, Room RK 3111
P.O. Box 20
NL-5340 BH Oss The Netherlands
+31 412 665464
+31 412 662546
jac.wijkmans@organon.com
www.kncv.nl

Organisation of one annual scientific meeting (1 day).
Co-organisation of Dutch Medicine Days (FIGON) (2 days).
Co-organisation of annual NWO platform meeting (2 days).
Co-organisation of sessions at KNCV Winter/Summer Congress.
Participation in KNCV, NWO, FIGON and EFMC platforms.
Dutch Pharmacocchemistry Award every 2 years for the best Dutch Ph.D. thesis in the field.

17th LACDR School on Medicinal Chemistry •
(October 28-31, 2008), Noordwijkerhout, The Netherlands
Alzheimer Disease, Medicinal Chemistry symposium •
(part of KNCV Spring Symposium)
(17 April 2008) Congrescentrum, De Reehorst, Ede, The Netherlands
28th Noordwijkerhout-Camerino-Cyprus Symposium on Trends in Drug •
Research (May 2009), Noordwijkerhout, The Netherlands

Prof. Dr. A.P. IJZERMAN
(MEDICINAL CHEMISTRY/LACDR)
Dr. J.C.H.M. WIJKMANS
(N.V. ORGANON)
Dr. H.K.A.C. COOLEN
(SOLVAY PHARMACEUTICALS BV)
Prof. Henk TIMMERMAN
(VRIJE UNIVERSITEIT LACDR)

MISSION

FOUNDED MEMBERS MEMBER PROFILE

POSTAL ADDRESS

TELEPHONE FAX E-MAIL WEBSITE

ACTIVITIES

PRESIDENT

SECRETARY

TREASURER

EFMC-DELEGATE

TURKISH ASSOCIATION OF MEDICINAL AND PHARMACEUTICAL CHEMISTRY



MISSION	Establish communication and cooperation between the members. Establish policies in medicinal chemistry teaching and research in the country. Organise scientific meetings and conferences, get in touch with international related bodies.
FOUNDED	1994
MEMBERS	170
MEMBER PROFILE	Academics: 100%
POSTAL ADDRESS	Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Gazi University TR-06330 Ankara, Turkey
TELEPHONE	+90 312 222 72 25
FAX	+90 312 223 50 18
E-MAIL	mfsahin@gazi.edu.tr
WEBSITE	www.medchem.org
ACTIVITIES	Organising meetings and conferences.
PRESIDENT	Prof. Dr. M. Fethi SAHIN (GAZI UNIVERSITY)
EFMC-DELEGATE	Prof. Dr. M. Fethi SAHIN (GAZI UNIVERSITY)



THE BIOLOGICAL AND MEDICINAL CHEMISTRY SECTOR (BMCS) OF THE ROYAL SOCIETY OF CHEMISTRY (RSC)

The BMCS aims to further the interests of all members of the RSC, both industrial and academic, involved in the pursuit and understanding of biologically active molecules. It also acts to promote public awareness of the crucial role played by chemistry in the modern industrial environment.

1995 (Formerly Fine Chemicals & Medicinals Group)
1129 in total; 600 of whom are medicinal chemists
Predominantly industry

Royal Society of Chemistry - Burlington House - Piccadilly
GB-London W1J 0BA United Kingdom
+44 207 437 8656
+44 207 4937 8883
www.rsc.org/members/interestgroups/bmcs.index

MISSION

FOUNDED
MEMBERS
MEMBER PROFILE

POSTAL ADDRESS

TELEPHONE
FAX
WEBSITE
ACTIVITIES

The Biological and Medicinal Chemistry Sector (BMCS) is a Sector of the Industry & Technology Forum of the Royal Society of Chemistry (RSC) in the UK. The annually elected committee is primarily responsible for the organisation of scientific meetings and symposia, supporting educational activities in the UK, and advising the Society on policies that directly affect the BMCS. Specifically, the BMCS aims to further the interests of all members of the RSC, both industrial and academic, involved in the pursuit and understanding of biologically active molecules. The predominant areas thus include pharmaceuticals, agrochemicals, flavours and fragrances. It also acts to promote public awareness of the crucial role played by chemistry in the modern industrial environment. The BMCS is particularly active in the organisation of scientific meetings and does so in collaboration with a wide variety of other groups both within and external to the RSC. Over the past few years the BMCS has been especially active in promoting some of the important interfacial areas in which chemists are intimately involved. In recent years, it has held internationally attended meetings with the EFMC, the Society for Chemical Industry, the Society for Medicines Research and with the Biochemical Society. On average six or more scientific meetings are held each year. Support for educational activities, such as the running of lectures and day schools, and the provision of equipment are also an important component of BMCS activities. Indeed, some of these initiatives are now established as annual events. The BMCS also administers annual awards that acknowledge major scientific achievements in both academia and industry that have been carried out within the UK. The BMCS provides a significant input into Royal Society of Chemistry strategic initiatives.

- The Challenges of Multi-Target Drug Discovery (March 10, 2008), London, UK
- 19th Symposium on Medicinal Chemistry in Eastern England (April 2008), Hatfield, UK
- Drugs from Natural Products IV (April 7-8, 2008), Cambridge, UK
- Proteinase 2008: From Molecules to Medicines (April 21-22, 2008) London, UK
- Pharmacokinetics and Drug Metabolism for Chemists (June 11, 2008), Liverpool, UK
- GPCRs in Medicinal Chemistry II (September 8-12, 2008), Gothenburg, Sweden
- 2nd Coast to Coast Meeting (October 26-29, 2008), Poole, UK
- 4th Anglo-Swedish Medicinal Chemistry Symposium (March 2009), Åre, Sweden

Dr. David ALKER (DAVID ALKER ASSOCIATES)
Dr. Karl SWIFT (TOCRIS BIOSCIENCES)
Dr. Derek BUCKLE (DRB ASSOCIATES)

PRESIDENT
SECRETARY/TREASURER
EFMC-DELEGATE

MISSION	A multidisciplinary society with the object of advancing science relating to all aspects of medicines research, providing a common meeting ground for all those interested or involved in such research, and to further the education of such persons.
FOUNDED MEMBERS	1966 ca. 500
MEMBER PROFILE	Trade & Industry: 70% Research Institute: 5% University: 11% Other: 4%
POSTAL ADDRESS	840 Melton Road GB-Thurmaston, Leicester, LE4 8BN, United Kingdom
TELEPHONE FAX	+44 116 269 1048 +44 116 264 0141
E-MAIL WEBSITE	secretariat@smr.org.uk www.smr.org.uk
ACTIVITIES	The SMR organises four one-day scientific meetings per year in the UK. Examples of meeting topics: Improving medicines through drug delivery; The role of sodium channels in disease; Case histories in drug discovery; Trends in medicinal chemistry (More details are available on the SMR web site).
PRESIDENT	Dr. Alan PALMER (PHARMIDEX PHARMACEUTICAL SERVICES Ltd)
EFMC-DELEGATE	Dr. Richard ARMER (OXAGEN Ltd)

DIRECTORY OF COMPANIES

An alphabetical list of pharmaceutical companies, as well as manufacturers and suppliers of products and services for medicinal chemistry in Europe

A

3M	3M Center Corporate Headquarters	US	ST. PAUL, MN 55144-1000	
4SC AG	Am Klopferspitz 19a	DE	82152 MARTINSRIED	+49 89 700763 0
A & D INSTRUMENTS LTD	Abingdon Science Park	GB	ABINGDON OX14 3YX	+44 1235 550 420
AAF INTERNATIONAL BV	Egelenburg 2	NL	1081GK AMSTERDAM	+31 20 549 44 11
ABBOTT LABORATORIES	100 Abbott Park Rd	US	ABBOTT PARK IL 60064-3500	+1 847 937 6100
ABCR GMBH & CO KG	Im Schleiert 10	DE	76187 KARLSRUHE	49 721 950 61 16
ABGENE HOUSE	Blenheim Road	GB	EPSOM SURREY KT19 AP	+44 1272 72 34 56
ABSORPTION SYSTEMS	440 Creamery Way Suite 300	US	EXTON PA 19341	+1 610 280 7300
ACB BLOCKS LTD.	PO Box 10	RU	121609 MOSCOW	+7 495 761 4365
ACCELRYYS	334 Cambridge Science Park	GB	CAMBRIDGE CB4 0WN	+44 1223 228 500
ACROS ORGANICS	Geel West Zone 2 Janssen Pharmaceuticaal, 3A	BE	2440 GEEL	+32 014 57 52 11
ACTELION	Gewerbestrasse 16	CH	4123 ALLSCHILL	+41 61 487 45 45
ACTIVE MOTIF	Avenue Franklin Roosevelt 104 Box 25	BE	1330 RIXENSART	+32 2 653 00 01
ADAMS HEALTHCARE	Lotherton Way Garforth	GB	LEEDS LS25 2JY	+44 1132 320 066
ADELPHI MANUFACTURING CO.LTD	Olympus House Mill Green Road	US	HAYWARDS HEATH RH16 1XQ	+44 1444 440 091
ADHESIVES RESEARCH INC	400 Seaks Run Road PO BOX 100	GB	GLEN ROCK PENNSYLVANIA 17327	+1 717 357 979
ADPAK MACHINERY SYSTEMS LTD	3 Pendleside Lomeshaye Industrial Estate	GB	NELSON BB9 6RY	+44 1282 601 444
AERNI-LEUCH AG/KLOCKNER	Sportweg 38	CH	3097 LIEBEFELD/BERNE	+41 31 978 88 88
AEROMATIC-FIELDER LTD	PO BOX 15	GB	EASTLEIGH SO53 4ZD	+44 2380 267 131
AFLEX HOSE LTD	Spring Bank Industrial Estate Watson Mill Lane	GB	HALIFAX HX6 3BW	+44 1422 317 200
AGILENT TECHNOLOGIES	Pegasus Park - De Kleetlaan 12A bus 12	BE	1831 DIEGEM	02 404 92 22
AIS CLEANROOM PRODUCTS LTD	Unit 33 Riverside Medway City Estate	GB	ROCHESTER ME2 4DP	+44 1634 719 422
AKZO NOBEL NV	Velpenweg 76	NL	6824 BM ARHNEEM	+31 26 366 44 33
ALCON LABS	6201 S. Freeway (T1-3)	US	FORT WORTH TEXAS 7 6134-2099	+44 1948 880 627
ALERT PRODUCTS	Hollins Lane Tilstock	GB	WHITCHURCH SY13 3NU	+49 219 1795 216
ALEXANDERWERK AG	Kippdorffstrasse 6-24	DE	42857 REMSCHEID	+49 721 94007 280
ALFA AECASAR GMBH & CO KG	Postbox 11 07 65	DE	76057 KARLSRUHE	+46 85 306 5000
ALFA LAVAL TUMBA AB	Hans Stahles vag	SE	14780 TUMBA	+44 1753 443 344
ALLCHEM INTERNATIONAL LTD	Broadway House 21 Broadway	US	MAIDENHEAD SL6 1NJ	+1 714 246 4500
ALLERGEN INC.	P.O. Box 19534	GB	IRVINE CA	+44 1767 691 100
ALL-FILL INTERNATIONAL LTD	Unit 5 Gateshead Close- Sunderland Road	GB	SANDY SG19 1RS	+34 93 291 30 00
ALMIRALL PRODESFARMA SA	General Mitre, 151	ES	8022 BARCELONA	+49 7531 84 3028
ALTANA PHARMA AG	Byk-Gulden-Strasse 2	DE	78467 KONSTANZ	+44 1462 480 480
ALTRO FLOORS	Works Road	GB	LEITCHWORTH SG6 1NW	+31 72 527 34 00
AMAFILTER	Kwakelkade 28 Postbus 396	NL	1800 AJ ALKMAAR	+44 1789 204 288
AMEC	Timothy's Bridge Road	GB	STRAFORD UPON-AVON CV37 9NJ	+44 1494 544000
AMERSHAM PLC	Amersham Place Little Chalfont	GB	THOUSAND OAKS CA 91320-1799	+1 805 447 1000
AMGEN INC.	One Amgen Center Drive	US	BUDAPEST	+32 9 253 60 30
AMRI	Z hony u. 7	BE	9940 EVERGEM	+32 5 371 05 05
ANABIOTEC NV	Reibroekstraat 13	BE	9300 AALST	+44 1189 750 998
ANSELL OCCUPATIONAL HEALTHCARE	Wijngaardveld 34 C	GB	EARLEY RG6 RAZ	+44 1672 518 350
APPLESHAW ASSOCIATES	7 Ryhill Way	GB	MARLBOROUGH SN8 1LZ	+31 10 462 18 55
APPLIED PRECISION INC	121 High Street	FR	78232 LE PECQ CEDEX	+33 1 30 09 40 00
APPLIKON DEPENDABLE INSTRUMENT	De Brauwweg 13 PO BOX 149	NL	3100 AC SCHIEDAM	+44 1279 645 674
AQUALON FRANCE	54 Route de Sartrouville	GB	HARLOW ESSEX CM19 5TR	+44 1425 478 781
ARGENTA DISCOVERY LTD	8/9 Spire Green Centre Flex Meadow	BE	2060 ANTWERPEN	+32 3 206 93 70
ARMFIELD LTD	Bridge House West Street	CH	4142 MUNCHENSTEIN	+41 61 417 96 60
ARPADIS NV	Samberstraat 7	US	WOBURN MA 01801-5140	+1 781 994 0300
ARPIDA	Dammstrasse 36	US	BOULDER CO 80301	+1 303 381 6645
ARQULE	19 Presidential Way	RU	123182 MOSCOW	+7 095 109 3324
ARRAY BIOPHARMA	3200 Walnut Street	GB	CAMBRIDGE CB4 0WE	+44 1223 226 200
ASINEX LTD	6 Schukinskaya ulitsa	GB	STOKE MANDEVILLE HP22 5TG	+44 1296 614 144
ASTEX TECHNOLOGY LTD	250 Cambridge Science Park Milton Road	GB	LONDON W1K 1LN	+44 (0)20 7304 5000
ASTON SCIENTIFIC LTD	Silverdale House 111 Wendover Road			
ASTRA ZENECA PLC	15 Stanhope Gate			

ASTRAZENECA



1, place Louis Renault - 92844 Rueil-Malmaison
FRANCE

► www.astrazeneca.fr

Tel: +33 1 41 29 40 00
Fax +33 1 41 29 40 01

ATLAS MATERIAL TESTING TECHNOLOGY BV
 ATOS ORIGIN
 AUTODOSE SA
 AVENTIS PHARMACEUTICALS INC.
 AVERY BERKEL
 B. BRAUN MEDICAL
 BASF AG
 BAYER AG
 BCH LTD
 BD BIOSCIENCES BENELUX
 BEAUFOR IPSEN INTERNATIONAL SNC
 BEECHWOOD RECRUITMENT LTD
 BEMAS INTERNATIONAL PACKAGING LTD

Aalsvoort 69 PO BOX 182 (7241 MA)
 3 Place de la Pyramide
 18 Chemin des Aulx
 300 Somerset Corporate Boulevard
 Foundry Lane
 Carl-Braun-Strasse 1
 Carl-Bosch-Strasse 38
 Kaiser Wilhelm Allee 1
 Spring Place Millfold
 POB 13 Eredebodegem-Dorp 86
 37 rue Spontini
 221 High Street
 Bemas House 9 Accommodation Road Golders Green

NL 7240 AD LOCHEM
 FR 92067 PARIS - LA DEFENSE CEDEX
 CH 1228 GENEVA
 US BRIDGEWATER NJ 08807-2854
 GB SMETHWICK B66 2LP
 DE 34212 MELSUNGEN
 DE 67056 LUDWIGSHAFEN
 DE 51373 LEVERKUSSEN
 GB WHITWORTH OL12 8DN
 BE 9320 EREMBODEGEM
 FR 75116 PARIS
 GB LONDON W3 9BY
 GB LONDON NW11 8ED

+31 57 325 64 65
 +33 1 49 00 90 00
 +41 22 884 13 30
 +1 800 981 2491
 +44 8709 050 064
 +49 (0) 56 61 71-0
 +49 (0) 621 60-0
 +49 (0) 214 301
 +44 1706 852 122
 +32 53 720 600
 +33 2 37 62 89 00
 +44 2039 928 647
 +44 2084 580 440

BENTHAM SCIENCE PUBLISHERS LTD.

P.O. Box 294, 1400 AG Bussum
 THE NETHERLANDS

subscriptions@bentham.org
 www.bentham.org



A major STM publisher of both subscription and open access journals, Bentham Science answers the information needs for the pharmaceutical, bio-medical and medical research communities. Leading journals include **CURRENT DRUG METABOLISM** (Impact Factor 5.76), **CURRENT CANCER DRUG TARGETS** (Impact Factor 5.67), **CURRENT PHARMACEUTICAL DESIGN** (Impact Factor 5.27) and **CURRENT MEDICINAL CHEMISTRY** (IF 5.20), the leading review journal in its field and endorsed by 7 Nobel Laureates.

New in 2007 and 2008: Ten Patent Review Journals in drug design and discovery!

Visit us online at www.bentham.org and www.bentham.org/open For subscriptions contact subscriptions@bentham.org

BIACORE
 BIO PURE TECHNOLOGY LTD
 BIOCATALYSTS LTD
 BIOENGINEERING AG
 BIOGAS FERMENTATION AB
 BIOGEN INC
 BIOGENEX
 BIOGLAN LABORATORIES LTD
 BIOIBERICA SA
 BIOLINE UK INC
 BIOMATECH SA
 BIOMEDTECH LABORATORIES INC
 BIOPHARMA PROCESS SYSTEMS
 BIOPROSPERIVE
 BIOQUELL PHARMA
 BIO-RAD LABORATORIES
 BIORELIANCE LTD
 BIOROBOTICS
 BIOSEPPA SA
 BIOTAGE AB
 BIOTAGE UK LTD
 BIOTECHNIQUES
 BIOTEST AG
 BISCHOFF ANALYSENTECHNIK GMBH
 BMG LABTECHNOLOGIES GMBH

Raspagatan 7
 17 South Street
 Treforest Industrial Estate
 Sagenrainstrasse 7
 PO Box 965
 14 Cambridge Center
 4600 Norris Canyon Road
 «North Way/Walworth Industrial Estate»
 Plaza Francisc Macia 7
 16 The Edge Business Centre Humber Road
 Zone Industrielle de l'Isle 115 Rue Pasteur
 6408 East Fowler Avenue
 Biopharma House Winnall Valley Road
 Place Colbert 24 Bis rue Jacques Boutrolle BP 24
 Walworth Road
 Fokkerstraat 10
 Innovation Park Hillfoots Road
 Barton Road Haslingfield
 48 Avenue des Genettes
 Kungsgatan 76
 15 Harford Court Fox Holes Business Park John Tate Rd
 One Research Drive Suite 400A PO BOX 1070
 Landsteinstrasse 5
 Boebingerstrasse 23
 Hanns Martin Schleyer Strasse 10

SE 754 50 UPPSALA
 GB HAVANT PO9 1BU
 GB PONTYPRIDD CF37 5UD
 CH 8636 WALD
 SE 22009 LUND
 US CAMBRIDGE MA 2142
 US SAN RAMON, CA 94583
 GB ANDOVER SP10 5AZ
 ES 8029 BARCELONA
 GB LONDON NW2 6EW
 FR 38670 CHASSE-SUR-RHONE
 US TAMPA, FL 33617-2404
 GB WINCHESTER SO23 0CD
 FR 76131 MONT- SAINT - AIGNAN CEDEX
 GB ANDOVER SP10 5AA
 NL 3905 KV VEENENDAAL
 GB STIRLING FK9 4NF
 GB CAMBRIDGE CB3 7LW
 FR 95800 CERGY ST CHRISTOPHE
 SE 75318 UPPSALA
 GB HERTFORD HERTS SG13 7NW
 US WESTBOROUGH, MA 01581-1070
 DE 63303 DREIEICH
 DE 71229 LEONBERG
 DE 77656 OFFENBURG

+46(0)18 675700
 +44 2392 499 000
 +44 1443 843 712
 +41 55 256 82 09
 +46 46 280 1700
 +1 617 679-2000
 +1 925 275 0550
 +44 1264 363 117
 +34 93 490 4908
 +44 2088 305 300
 +33 4 78 07 92 34
 +1 813 985 7180
 +44 1962 841 092
 +33 2 32 10 11 70
 +44 1264 835 853
 +31 31 854 06 66
 +44 1786 451 318
 +44 1223 873 500
 +33 1 34 20 78 00
 +46 18 56 59 00
 +44 1 992 501 535
 +1 508 614 1414
 +49 610 3801 0
 +49 715 2606 40
 +49 781 9696 80

BOEHRINGER INGELHEIM PHARMA GMBH & Co. KG

Birkendorfer Str. 65, 88397 Biberach an der Riss
 GERMANY

www.boehringer-ingelheim.com

Tel: +49 7351 540



BOEHRINGER INGELHEIM - VALUE THROUGH INNOVATION

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 152 affiliates in 45 countries and more than 38,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

BOOTS GROUP PLC
 BOVINS LEAD LEASE PHARMACEUTICAL
 BRAN & LUEBBE GMBH

1 Thane Road
 Tanshire House Shackleford Road
 Werkstrasse 4

GB NOTTINGHAM NG2 3AA
 GB ELSTED GUG 6LB
 DE 22844 NORDERSTEDT

+44 1252 703 663
 +49 405 2202 554

BOROCHEM SAS



BOROCHEM
boron building blocks for chemist

Immeuble Emergence - 7, rue Alfred Kastler - 14000 Caen
FRANCE

► **ALEXANDRE BOUILLON**, Chief Scientific Officer
CHRISTINE LE BORGNE, Sales Manager
sales@borochem.fr - www.borochem.fr
Tel: +33 231 945 073 - Fax: +33 231 462 651

BoroChem efficiently delivers innovative and exclusive organoboron building blocks to organic and medicinal chemists from the biotech pharmaceutical, cosmetic and agrochemical industries. Our offer includes rare and versatile boronic acids and esters, boro-amino acids, halogeno heterocyclic compounds and custom synthesis from mg to multi kilos quantities to support your R&D efforts.

BRECONCHERRY LTD
BREVETTI CEA SPA
BRISTOL MYERS SQUIBB
BRUKER DALTONIK GMBH
BUCHI LABORTECHNIK AG
BURGMANN DÜSTUNGSMERKE GMBH & CO. KG
C S CONSULTANTS
CADCENTRE INTERNATIONAL LTD
CALEVA PROCESS SOLUTIONS LTD
CALIPER LIFESCIENCES
CAMAG
CAMBRIDGESOFT CORP
CANONGATE TECHNOLOGY LTD
CAPSULIT SPA
CARL ZEISS
CBISS LTD
CEBIPHAR
CECIL INSTRUMENTS LTD
CELERA GENOMICS
CELITE FRANCE SA
CELL THERAPEUTICS INC.
CEM CORP.
CEPHALON INC.
CEREP
CERMEX
CHARWOOD MOLECULAR LTD
Lower Road Trading Estate
Via Del Commercio 28 (ZAI)
345 Park Avenue
Fahrenheitstrasse 4
Meierseggstrasse 40
Aeusserer Sauerlacher Strasse 6-10
3 rue Imlin
High Cross Madingley Road
Butts Pond Industrial Estate
ZAC PARIS-NORD II 13 rue de la Perdrix BP 40016
Sonnenmattstrasse 11
8 Signet Court, Swanns Road
36 Inglis Green Road
Via Lombardia 5
Ikaroslaan 9
11 Ark Royal Way Lairside Technology Park
Route de Pernay
Milton Technical Centre Milton
45 West Gude Drive
7, Rue du Stade
201 Elliot Ave. West, Suite 400
PO BOX 200
145 Brandwine Parkway
128 Rue Danton
87 Route de Seurre BOX BP 3
The Heritage Building 7 Beaumont Court Prince William Road

GB LEDBURY HR8 2DH +44 1531 632 476
IT 36050 SOVIZZO +39 4 445 36 241
US NEW YORK 10154 +1 212 546 4000
DE 28359 BREMEN +49 421 2205 200
CH 9230 FLAWIL 41 71 394 63 63
DE 82515 WOLFRATSHAUSEN +49 817 1230
FR 67100 STRASBOURG +33 3 88 40 38 65
GB CAMBRIDGE CB3 0HB +44 1223 556 655
GB STURMINSTER NEWTON DT10 1AZ +44 1258 471 122
FR 95911 ROISSY CHARLES DE GAULLE CEDEX +33 1 48 63 7135
CH 41321 MUTTENZ +41 61 467 34 34
GB CAMBRIDGE CB5 8LA +44 1223 464900
GB EDINBURGH EH14 2ER +44 1314 557 211
IT 20040 RONCELLO MI +39 3 962 78 51
BE 1930 ZAVENTEM +2 719 39 11
GB BIRKENHEAD CH41 9HT +44 1516 668 300
FR 37230 FONDETTES +33 2 47 42 48 48
GB CAMBRIDGE CB4 6AZ +44 1223 420 821
US ROCKVILLE, MD 20850 +1 240 453 3000
FR 92745 MURAT +33 1 71 20 00 49
US SEATTLE, WA 98119 1 206 213 8315
US MATTHEWS NC 28106-0200 +1 704 821 7015
US WEST CHESTER PA 19380 +1 610 738 6384
FR 92506 RUEIL- MALMAISON CEDEX +33 (0)1 45 64 44 60
FR 21910 CORCELLES-LES-CITEAUX +33 3 80 70 71 00
GB LOUGHBOROUGH LE11 5GA +44 (0)1509 232007

CHEMBRIDGE CORPORATION



16981 Via Tazon, Suite G - 92127 San Diego, California
USA

sales@chembridge.com
www.chembridge.com
www.chembridgeresearch.com
Tel: +1 858 451 7400 - Fax: +1 858 451 7401

ChemBridge offers an extensive portfolio of advanced discovery chemistry products and contract research services, including over 700,000 drug-like, diverse, small molecule compound collections and diverse & targeted in-house parallel-synthesized screening libraries (200,000 cmps total), as well as customized discovery chemistry research services. ChemBridge Corporation together with ChemBridge Research Laboratories, Inc. (CRL) provide a comprehensive portfolio of efficient and cost-effective enabling chemistry solutions for all stages of small molecule drug discovery, from initial hit generation, to hit-to-lead, to lead optimization and pre-clinical candidate identification.

CHEMDIV INC.
CHEMICAL ABSTRACT SERVICE (CAS)
CHEMICAL COMPUTING GROUP INC
CHEMICAL DIVERSITY EUROPE
CHEMISCHE FABRIK BERG GMBH
CHERWELL LABORATORIES LTD
CHILWORTH TECHNOLOGY LTD
CHIRAL
CHROMACOL LTD
CIBA SPECIALITY CHEMICALS INC.
CIPHERGEN BIOSYSTEMS
CLEAN ROOM CONSTRUCTION LTD
CLYDE MATERIALS HANDLING LTD
COHESIVE TECHNOLOGIES
COLDSTREAM LTD
COLLETTE
COLORCON LTD
11558 Sorrento Valley Road Suite 5
2540 Olentangy River Road Columbus
Sherbrooke Street West 1010, Suite 910
The Vision Centre 5 Eastern Way Bury St.Edmunds
Mainthallstrasse 3
1 Murock Road
Beta House Chilworth Science Park
NEXT PAGE
3 Mundells Industrial Centre Welwyn Garden City
P.O. Box 1130
6611 Dumbarton Circle
Units K1/K2 Temple Court Knight Road Strood
Shaw Lane Industrial Estate
17 Cochran Close
Olympus House Mill Green Road
Keerbaan 70
Flagship House Victory Way Crossways
US SAN DIEGO, CA 92121 +1 858 794 4860
US OHIO 43210-0012 +1 614 447 3600
CA MONTREAL QUEBEC H3A 2R7 +1 514 393 1055
GB SUFFOLK IP23 7AB +44 1284 749 698
DE 6749 BITTERFELD +49 349 3781 80
GB BICESTER OX26 4XB +44 1869 355 500
GB SOUTHAMPTON SO16 7NS +44 2380 760 722
GB HERTS AL7 1EW +44 1707 394 949
CH 4002 BASEL +1 510 505 2100
US FREMONT CA 94555 +44 1634 295 111
GB ROCHESTER ME2 2LT +44 1302 321 313
GB DONCASTER DN2 4SE +44 1908 267 355
GB CROWN HILL MILTON KEYNES MK8 0AJ +44 1444 440 091
GB HAYWARDS HEATH RH16 1XQ +32 3 350 12 11
BE 2160 WOMMELGEM +44 1322 293 000
GB DARTFORD KENT DA2 6GD

CHIRAL TECHNOLOGIES EUROPE

Boulevard Gonthier d'Andernach - BP 80140
67404 Illkirch Cedex
FRANCE

FRÉDÉRIC CHEVIRON ◀

cte@chiral.fr

www.chiral.fr

Tel: +33 388 79 52 00 - Fax: +33 388 66 71 66



CHIRAL TECHNOLOGIES specializes in enantiomeric separation products and services for the pharmaceutical industries. The company assists customers throughout the drug development process, from initial analysis to production of the finished product.

- DAICEL HPLC columns and bulk chiral stationary phases,

- Analytical method development

- Customers who do not have time or available facilities to produce single enantiomer compounds at the preparative or pilot plant scale can take advantage of the Custom Separation Service that utilizes chromatographic resolution technology. The facility complies with cGMP and GLP guidelines, and is available for separation of racemates.

CONCEPT GMBH
CONFARMA AG
COPLEY SCIENTIFIC LTD
COTTENHAM INSTRUMENTS AND MATERIALS
COVANCE LABORATORIES LTD
CRYSTALLICS
CURRENT DRUGS LTD
CYBIO
CYTOMATION BIOINSTRUMENTS GMBH
CYTOMYX
CYTOMYX BENELUX
DANISH UNIVERSITY OF PHARMA. SC.
DASTEX GMBH
DE LAMA SPA
DELPHIA LABORATOIRES
DERWENT INFORMATION
DIEMME
DIVERCHIM
DMN MACHINEFABRIEK BV
DOMINICK HUNTER LTD
DOVIANUS BV
DOYEN MEDIPHARM LTD
DRAM ANLAGENBAU GMBH
DRUG DISCOVERY TODAY
DSM BIOLOGICS
DUMOULIN
DYCEM LTD
ECLIPSE SCIENTIFIC GROUP
ECOLOCHEM INTERNATIONAL INC
EDL PACKAGING ENGINEERS LTD
EFO INTERNATIONAL INC
ELI LILLY & CO
ELIZABETH COMPANIES
ELLAB AS

Rischerstrasse 8
Emil Frey Strasse 39
Private Road 7 Colwick Industrial Estate
34 Histon Road Cottenham
Otley Road
Zakeringstraat 29
34-42 Cleveland Street Middlesex House
G'schwiitz Strasse 40
Engesserstrasse 4
6-7 Techno Park Newmarket Road
Dreijenlaan 2 Gebouw 304
Drug Research Academy Universitetsparken 2
Draisstrasse 23
Via Piemonte N 21
1 Allée de la Chartreuse ZI Petite Montagne Nord CE 1450
14 Great Queen Street
Via Badazzo 1
Les Marches de l'Oise 100 Rue Louis Blanc
Gravendamsweg 16 PO BOX 6
Process Filtration Durham Road Birtley
Terbregseweg 120
Cavendish House Cambridge Road
Aspenweg 19-21
84 Theobald's Road
Poststraat 1 PO BOX 43
5 Rue A. Perdonnet ZI Le Closeau
Ashley Trading Estate Ashley Parade
Medcalfe Way Bridge Street
Hydrohouse Newcombe Way Orton Southgate
Upcott Avenue Nottingham Business Park
Unit 14 Apex Business Centre Boscombe Road
Lilly Corporate Center
Ysselaarlaan 15/B
Krondalvej 9

DE 69123 HEIDELBERG +49 622 1844 40
CH 4142 MÜNCHENSTEIN/BASLE +41 61 337 92 00
GB NOTTINGHAM NG4 2ER +44 115 961 6229
GB CAMBRIDGE CB4 8UD +44 1954 252 208
GB HARROGATE N YORKS HG3 1PY +44 1423 500 888
NL 1014 BV AMSTERDAM +31 20 586 80 31
GB LONDON W1T 4LB +44 2075 808 393
DE 7745 JENA +49 364 1351 0
DE 79108 FREIBURG IM BREISGAU +49 761 5597 370
GB CAMBRIDGE CB5 8PB +44 1223 508 191
NL 6703 HA WAGENINGEN +31 317 419 243
DK 2100 COPENHAGEN O +49 722 2969 660
DE 76461 MUGGENSTRUM +39 3 825 59 501
IT 27028 SAN MARTINO SICCOMARIO +33 1 607 79 36 47
FR 91020 EVRY CEDEX +44 2073 442 999
GB LONDON WC2B 5DF +39 5 452 06 11
IT 48022 LUGO +33 4 44 64 61 90
FR 60765 MONTAIRE CEDEX +31 25 236 18 00
NL 2210 AA NOORDWYKERHOUT +44 1914 105 121
GB DURHAM DH3 2SF +31 10 420 60 11
NL 3056 JX ROTTERDAM +44 1223 264 300
GB BARTON CB3 7AR +49 754 1970 30
DE 88097 ERIKIRCH BODENSE +44 2076 114 400
GB LONDON WC1X 8RR +31 46 477 3343
NL 6130 AA SITTARD +33 1 64 84 50 00
FR 77220 TOURNAN EN BRIE +44 1179 559 921
GB BRISTOL BS2 9BB +44 1354 695 858
GB CHATTERIS PE16 6QZ +44 1733 390 179
GB PETERBOROUGH PE2 6SE +44 1271 345 351
GB BARMSTAPLE EX31 1HN +44 1582 666 334
GB DUNSTABLE LU5 4SB +1 317 276 2000
US INDIANAPOLIS IN 46585 +32 3 830 10 81
BE 2630 AARTSELAAR +45 4452 0500
DK 2610 ROEDOVRE

ELSEVIER LTD.

The Boulevard
Langford Lane, Kidlington, Oxford, OX5 1GB
UNITED KINGDOM

JAMES MILNE, Publisher - Organic and Inorganic Chemistry ◀

j.milne@elsevier.com

www.elsevier.com

Tel: +44 1865 843891 - Fax: +44 1865 843954



Elsevier: Publishers of leading international Medicinal Chemistry research, including Bioorganic & Medicinal Chemistry Letters, the 2nd highest cited journal in Medicinal Chemistry.

EMAX SOLUTION HEADQUARTER
EMCEL FILTER LTD
EMS-DOTTIKON AG
ENAMINE
ENERCOM INDUSTRIES LTD
ENTOMED SA
ENVAIR LTD
ERWEKA INTERNATIONAL AG

17 Campus Square
Blatchford Road
PO Box
Aleksandra Matrosova Str.23
64 Edison Road Rabans Lane Industrial Estate
Bariumatan 29
York Avenue Haslingden
Muehlematstrasse 17

US NEWTON SQUARE PA 19073
GB HORSHAM RH13 5RA
CH 5605 DOTTIKON
UA 1103 KYIV
GB AYLESBURY HP19 8UX
SE 213 64 MALMO
GB ROSSENDALE BB4 4HX
CH 4112 BAETTWIL

+1 610 325 3700
+44 1403 253 215
+41 56 616 81 11
380 44 537 32 18
+44 1296 330 542
+46 040-21 00 90
+44 1706 228 416
+41 61 735 90 50

ESTEVE QUIMICA SA
EUROGENTEC SA
EUROMED COMMUNICATION LTD
EUROPEAN INSTRUMENTS
EUROSCREEN
EUROVENT LTD
EVANS VACCINES LTD
EVOTEC OAI LTD
EXTRACT TECHNOLOGY LTD
FAMAR
FANUC ROBOTICS LTD
FCG LIFE SCIENCES OFFICE LOCATIONS
FERRING PHARMACEUTICALS AIS
F. HOFFMANN-LA ROCHE LTD
FIELD BLOOMER
FISHERPRINT LTD
FLEXICON AS
FLUENT EUROPE LTD
LUIDIGM
FORMULATION SA
FOURNIER PHARMA
FQS POLAND
FREEMAN TECHNOLOGY
FREESTAD PROCESS TECHNOLOGY LTD
FRESENIUS KABI GMBH
FREWITT SA
FRYMA KORUMA
FULCRUM SCIENTIFIC LTD.
FW PHARMA SYSTEMS
GALAPAGOS NV
GALPERMA INTERNATIONAL
GALLAY SYSTEMS LTD
GECI
GEDEON RICHTER LTD
GERHLICHER GMBH & CO KG
GENE-TI SA
GENEVAC LTD
GENFIT
GENOMICA
GEZYME PHARMACEUTICALS
GEORG FISCHER ANDERSON GMBH
GEORG THIEME VERLAG
GERRESHEIMER GLAS AG
GETINGE AB
GILSON INTERNATIONAL BV
GLATT GMBH
GLAXO WELLCOME UK LTD
GRIMLEY SMITH ASSOCIATES LTD
GRUNENTHAL GMBH
GTH CHIMIE FINE
GUERBET
H.LUNDBECK A/S
HADEN DRYSYS ENVIRONMENTAL LTD
HALTERMANN CUSTOM PROCESSING
HARBURG ENGINEERING CO. LTD
HARFORD CONTROL
HARLAND MACHINE SYSTEMS LTD
HAZARD EVALUATION LABORATORIES INC
HEA (HEALTH ENGINEERING AND ASSURANCE)
HELISINN
HENKEL-ECOLAB GMBH & CO OHG
HENOGEN SA
HETO-HOLTEN AS
HETICH-ZENTRIFUGEN GMBH & CO KG
HEWLETT PACKARD
HILGE PUMPS LTD
HITACHI INSTRUMENTS INC
HONEYMAN WATER LTD
HONEYWELL
HOVIONE FARMACIENCIA SA
I.P.M.
IBC USA CONFERENCES
ICDD
IBDS
IMMUCHEM
INCYTE CORPORATION
INDEX
INNOGENETICS
INNOTHERA
INPHARMATICA LTD
INTERBIOSCREEN LTD
INTERCHIM
INTERCOMPONENTWARE AG
INTERLAB
INTERNATIONAL PBI SPA

Avenida Mare de Deu de Montserrat 12
Parc Scientifique du Sart Tilman
The Old Surgery Liphook Road
Shotover Kilns Old Road
Rue Adrienne Bolland 47
Govan Road Fenton Industrial Estate Fenton
Gaskill Road Speke
151 Milton Park
Bradley Junction Industrial Estate Leeds Road
P. Marinopoulou Str. 174 56 Alimos
Seven Stars Industrial Estate Wheler Road
Tavistock House Tavistock Square
Key Fiskers Plads 11
Grenzacherstrasse 124
One Entrepise Way Mallusk Road
Padholme Road East
Fresasvej 2-6
Sheffield Airport Business Park Europa Link
7100 Shoreline Court
10 Impasse Borde Basse
42, rue de Longvic
Palac Pugetow ul. Starowislna 13-15
Boulters Farm Centre Castlemorton Common Weiland
Hunters Lodge, Chelvey Park Backwell Hill
Standort Neufahrn Zepelinstrasse 1
Route du Coteau 7 PO BOX 61
Theodorshofweg 6 Box Postfach 164
35-36 Lion Chambers, John William St.
Four Brindley Place
Generaal de Wittelaan L11 A3
Tour Europalaza La Défense 4 20, Avenue André Prothin
Wharfedale House 275 Wharfedale Road Tyseley
10 Rue Joseph-Marie Jacquard ZA Pesseliere PO BOX 73
PO Box 27
Robert Koch Strasse 5
147 Avenue Paul Doumer
The Sovereign Centre Farthing Road Sproughton
Parc Eurasanté 855 Rue Eugène Vinée
1745 38th Street
Sygena Facility Eichenweg 1
Hesslingsweg 71
Science of Synthesis R. idigerstrasse, 14
Moersbroicher Weg 191
Box 69
Laan van's-Gravenmade 80 PO box 3200
Buehlmuehle
Stockley Park West, Uxbridge
54 Bridge Street

72 Avenue Charles De Gaulle
BP 50400
Ottliavej 9
Swan Office Centre 1506-1508 Coventry Road Yardley
All Saints Refinery Cargo Fleet Road
Harbuc House Charlwoods Road
33 Harford Street
2 Michigan Avenue
4 Princess Road Suite 208
Keizer Karelsstraat 228
Via Industria 24
Postfach 130406
Rue des Professeurs Jeener et Brachet 12
Gydevang 17-19
Gartenstrasse 100
3000 Hanover Street
Hilge House Pelham Court
7 Ivanhoe Road - Hogwood Industrial Estate Finchampstead
Hamire Enterprise Park Barnard Castle
Moult Pleasant Middlezey
Quinta de S. Pedro Sete Casas
Zi Le Treill
One Research Drive, Suite 400 A PO BOX 5195
12 Campus Boulevard Newton Square
2 Occam Court The Surrey Research Park
Rue de la Station, 19
Experimental Station - E336 Route 141 & Henry Clay Road US
Via Nazionale 5
Technologiepark 6
7-9, Avenue François-Vincent Raspail B.P. 12
1 New Oxford Street
PO BOX 218
23 Allée Sanderus
Otto Hahn Strasse 3
Luise Kieselbach Platz No 35
Via Novara 89

ES 8024 BARCELONA
BE 4102 SERAING
GB HASLEMERE GU27 1NL
GB HEADINGTON OX3 8ST
BE 6041 GOSSELIES
GB STOKES-ON-TRENT ST4 2RS
GB LIVERPOOL L24 9GR
GB ABINGDON OXON OX 14 4SD
GB HUDDERSFIELD HD2 1UR
GB ATHENS
GB COVENTRY CV3 4LB
GB LONDON WC194
DK 2300 COPENHAGEN S
CH 4070 BASEL
GB NEWTOWNABBAY BT36 4EW
GB PETERBOROUGH PE1 5UL
DK 4100 RINGSTED
GB SHEFFIELD S9 1XU
US SOUTH SAN FRANCISCO, CA94080
FR 31240 L'UNION
FR 21300 CHENOVE
PL 31-038 KRAKOW
GB MALVER WR13 6LE
GB BRISTOL BS48 3DA
DE 85375 NEULFAHRN
CH 1706 FRIBOURG
CH 4310 RHEINFELDEN
GB HUDDERSFIELD HD1 1ER
GB BIRMINGHAM B1 2JB
BE 2800 MECHELEN
FR 92927 LA DEFENSE CEDEX
GB BIRMINGHAM B11 2LQ
FR 69780 MOINS
HU 1103 BUDAPEST
DE 82547 EURASBURG
FR 92500 RUEL-MALMAISON
GB IPSWICH SUFFOLK IPI 5AP
FR 59120 LOOS-LEZ-LILLE
US BOULDER COLORADO 80301
CH 4410 LIESTAL
DE 44309 DORTMUND
DE 70469 STUTTGART
DE 04070 DUSSELDORF
SE 31044 GETINGE
NL 2495AJ DEN HAAG
DE 79589 BINZEN
GB BRIGG DN20 8NS
DE 52099 AACHEN
FR 60260 LAMORLAYE
FR 95943 ROISSY CHARLES DE GAULLE CEDEX
DK 2500 VALBY
GB BIRMINGHAM B25 8AD
GB MIDDLESBROUGH TS3 6AF
GB EAST GRINSTEAD RH19 2HG
GB TROWBRIDGE BA14 7HL
GB SALFORD M6 2GY
US LAWRENCEVILLE NJ 08648
BE 9000 GENT
CH 6710 BIASCA
DE 40554 DUSSELDORF
BE 6041 CHARLEROI
DK 3450 ALLEROED
DE 78532 TUTTLINGEN
US PALO ALTO CA 94304-1185
GB CRAWLEY RH11 9AZ
GB WOKINGHAM BERKSHIRE RG40 4QQ
GB COUNTY DURHAM DL12 8BN
GB BRIDGWATER SOMERSET TA7 0NY
PT 2671 LOURES
FR 47520 LE PASSAGE D'AGEN
US WESTBOROUGH, MA 0158-5195
US PA 19073
GB GUILFORD, SURREY GU2 5QB
BE 1300 LIMAL
US WILMINGTON DE 19880
IT 40067 RASTIGNANO
BE 9052 GHENT
FR 94111 ARCUEIL CEDEX
GB LONDON WC1A 1NU
RU MOSCOW 121019
FR 59650 VILLNEUVE D'ASCO
DE 69190 WALLDORF
DE 81377 MUNICH
IT 20153 MILANO

+34 93 254 4000
+32 4 366 61 00
+44 1428 656 665
+44 1865 750 375
+32 71 348 500
+44 1782 744 242
+44 1517 055 051
+44 1235 441621
+44 1484 432 727
+30 1 098 98 500
+44 2476 639 669
+44 2078 746 700
+45 88338834

+44 1232 804 000
+44 1733 341 444
+45 5767 1155
+44 1142 818 888
+1 650 266 6075
+33 5 62 89 29 29

+48 12 429 43 45
+44 1684 310 860
+44 1275 463 706
+49 8165 901 0
+41 26 460 74 00
+41 61 836 20 00
+44 148 431 7214
+44 1216 227 557
+32 15342976
+33 1 58 86 45 45
+44 1217 655 800
+33 4 78 20 65 25
+36 1 431 4000
+49 817 9801 5
+33 1 41 96 80 30
+44 1473 240 000
+33 3 20 16 40 00
+1 720 565 4500
+41 61 906 59 59
+49 231 9256 0
+49 711 8931 0
+49 211 6181 00
+46 35 155 500
+31 70 307 36 00
+49 762 1664 375
+44 20 8990 9000
+44 1652 600 600
+49 241 569-0
+33 4 24 61 20 30
+33 1 45 91 50 00
+45 36 30 13 11
+44 1217 654 040
+44 1642 248 555
+44 1342 315 775
+44 1225 764 461
+44 1618 484 800
+1 609 912 1551
+32 9 223 68 03
+41 91 873 01 00
+49 211 9893 203
+32 71 37 89 02
+45 4816 6200
+49 746 1705 0
+1 650 857 1501
+44 1293 514 433
+44 1188 328 632
+44 1833 690 101
+44 1823 698 809
+35 1 21 982 9386
+33 5 53 68 53 86
+1 508 616 5550
+1 610 325 9814
+44 1483-595000
+32 4 337 40 53
+1 302 498 6700
+39 5 162 02 411
+32 9 329 13 29
+33 1 46 15 19 00
+44 2070 744 600
+7 095 913 2319

+49 622 7385 0
+49 897 4139 30
+39 2 487 79 1

+44 2088 300 803
+44 1875 614 545
+ 49 721 6189 100
+1 215 386 0100
+44 1737 377 061
+49 210 4954 0
+33 2 99 99 37 37
+44 1371 820 122
+41 91 695 17 40

JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH & DEVELOPMENT

Division of Janssen Pharmaceutica N. V.
Turnhoutseweg 30, 2340 Beerse
BELGIUM

FREDERIK WITTOCK, Senior Director Cross-Pharma R&D Communications ◀

fwittock@prdbe.jnj.com

www.inj.com

Tel: +32 14 60 57 24 - Fax: +32 14 60 52 77



JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH & DEVELOPMENT (J&JPRD) is one of the fastest-growing global pharmaceutical research & development (R&D) companies and part of the world's most comprehensive and broadly based healthcare company, Johnson & Johnson. With more than 3,500 employees, our R&D reach extends to more than 70 countries worldwide.

+44 1763 253 000
+44 1443 811 811
+44 1162 542 390
+34 93 770 0877
+49 405 5586 60
+1 734 665 8083
+49 723 1143 350
+31 34 550 99 00

KEY ORGANICS

Highfield Industrial Estate - Camelford - Cornwall PL32 9QZ
UNITED KINGDOM

ELIZABETH JONES, Business Development Executive for Europe ◀

elizabethj@keyorganics.ltd.uk

www.keyorganics.co.uk

Tel: +44 (0)1840 212137 - Fax: +44 (0)1840 213712



Key Organics Ltd offers over 20 years experience in providing custom synthesis and FTE chemistry services for: early drug discovery, hit-to-lead, library design and synthesis, lead-optimisation, process development and scale-up projects. Key Organics' trading arm, BIONET, produce and supply the BIONET Screening and Intermediate compounds - currently numbering over 46,000 and 4,700 respectively.

+358 9 6811 920
+41 41 259 65 65
+44 2083 345 500
+49 514 7976 0
+49 304 3576 145
+49 763 1706 70
+44 1628 532 211
+44 1933 408 500
+44 1942 845 000
+44 1481 867 321
+44 (161) 482 24 30
+33 1 46 29 99 60
+34 93 736 970
+33 6 93 62 38 50
+33 3 80 44 70 00
+34 93 446 6000
+44 1494 456 450
+44 1477 539 000
+49 625 7500 90
+44 1223 861 665
+44 1527 403 040
+44 8702 400 666
+1 614 675 3730
+39 64 135 31 31
+49 344 1292 313

LEICHLÉ SA
LEIRAS OY
LEO PHARMA/S
LEXIQUEST EUROPE
LIFE CHEMICALS EUROPE

BOX BP 90216
Pansionite 47 PO BOX 415
Industrieparken 55
Le Méliès 261 Rue de Paris
Gotenweg 10

FR 57400 SARREBOURG
FI 20101 TURKU
DK 2750 BALLERUP
FR 93556 MONTREUIL CEDEX
DE 38106 BRAUNSCHWEIG

+33 3 87 03 02 40
+358 2 330 6760
+45 72 26 23 53
+33 1 49 93 39 39
+49 531 28 01 97 60

LIFE CHEMICALS INC.



2477 Glenwood School Drive, Suite 203
Burlington, Ontario, L7R 3R9
CANADA

► **IRINA CHABANNY**, Director, Administration and Finance
lifchemicals@lifchemicals.com
www.lifchemicals.com

Telephone: +1(905)634-5212 - Fax: +1(905)634-4719

Producing and selling HTS compounds since 1995, Life Chemicals Inc. offers state-of-the-art and quality assured outsourcing: about 239 000 drug-like and lead-like compounds presented as template based libraries.

Targeted libraries (Kinase, Protease, Ion Channel, Nuclear Receptor, GPCR), Building blocks, Custom synthesis projects. Excellent service, reasonable prices.

LIQUENT
LOCK INSPECTION SYSTEMS
LOCUM INTERNATIONAL GROUP
LOHMANN & RAUSCHER INTERNATIONAL GMBH & CO. KG
LTE SCIENTIFIC LTD
M.Y. HEALTHCARE
MACFARLAN SMITH LTD
MACOFAR
MADAUS AG
MALVERN INSTRUMENTS LTD
MAP80 SYSTEMS LTD
MATRIX TECHNOLOGIES
MCKECHNIE PLASTIC COMPONENTS
MDL AG
MDL INFORMATION SYSTEMS INC
MDS NORDION
MEDEX
MEDICAL AIR TECHNOLOGY LTD
MEDICHEM
MEGGLE GMBH
MENARINI RICERCA SPA

ESPS House 56 London Road
Lock House Neville Street
50 Glad Avenue Industrial Center PO BOX 874
Westenwaldstraße 4
Greenbridge Lane Greenfield
Caxton Road
Wheatfield Road
Via Nazionale 5
Colonia-Allee 15
Grovevood Road
Unit 3 Kestrel Bus. Park Ivanhoe Road Finchamstead
Deanway Business Centre Wilmslow Road
Stamford Bridge
Gewerbestrasse 2
14600 Catalina Street
447 March Road
Unit 1 Woolleys Farm Welford Road
Aiology Centre Mars Street
2501 Davey Road
Megglesstrasse 6-12 PO BOX 40
Via Sette Santi 3

GB BAGSHOT GU19 5HL
GB OLDHAM OL9 6LF
IL KOCHAV YAIR 44864
DE 56579 RENGSDORF
GB OLDHAM OL3 7EN
GB BEDFORD MK41 0XZ
GB EDINBURGH EH11 2QA
IT 40067 RASTIGNANO
DE 51101 KOLN
GB MALVERN WR14 1XZ
GB WOKINGHAM RG40 4QQ
GB WILMSLOW SK9 3HW
GB YORK YO41 1AL
CH 4123 ALLSCHWIL 2
US SAN LEANDRO CA 94577
CA OTTAWA ON K2K 1X8
GB NASEBY NN6 7DP
GB OLDHAM OL9 6LT
US WOODBRIDGE IL 60517
DE 83512 WASSERBURG
IT 50131 FIRENZE

+44 1276 486 900
+44 1616 240 333
+972 9 7494 965
+49 2634 99-0
+44 1457 876 221
+44 1234 272 252
+44 1312 732 427
+39 5 162 02 411
+49 22 1 89 98 0
+44 1684 892 456
+44 1189 731 800
+44 1625 529 863
+44 1759 371 551
+41 61 486 88 88
+1 510 347 3541
+1 613 592 2790
+44 1858 575 065
+44 1616 216 200
+1 630 783 4600
+49 807 1733 29

MERCACHEM



Kerkenbos 1013, 6546 BB Nijmegen
P.O. Box 6747, 6503 GE Nijmegen
THE NETHERLANDS

► **Dr FRANK LEEMHUIS**
info@mercachem.com
www.mercachem.com

Telephone: +31 (0)24 372 3300 - Fax: +31 (0)24 372 3305

Mercachem is a CRO offering contract research and custom synthesis (mg to 0.5 kg) to support your Drug Discovery programs. Services include parallel synthesis of focused libraries and synthesis of monomers, scaffolds and standards for further research.

MERCK & CO INC.
MERLIN DIAGNOSTIC SYSTEMS BV
MICRO-MACINATION SA
MICROMERITICS LTD
MICRON TECHNOLOGIES
MILESTONE INC.
MILLIPORE CORPORATION
MINOTOPES FRANCE
MOEHS IBERICA SL
MOLECULAR DEVICES LTD
MOLECULAR FINE CHEMICALS
MONACHEM
MORPHOSYS AG
MRC SYSTEMS LTD
MUNTERS LTD

One Merck Drive P.O. Box 100
Charles Pettitweg 37-9
Via Cantonale
Unit 2 Chestnut House 178-182 High Street North
Crossways Boulevard Crossways
20 Mountain Rd
80 Ashby Road Bedford
4 Place de la Defense
Poligono Ind. Rubi Sur Cesar Martinelli Brunet 12A
135 Wharfedale Road Wimmersh Triangle
Zl du Chapelier BP 83
3 Rue du Gabian
Lena Christ Strasse 48
Elm House Shackelford Road
Blackstone Road

US WHITEHOUSE STATION, NJ 08889-0100
NL 4827 HJ BREDA
CH 6995 MONTEGGIO
GB DUNSTABLE LU6 1AT
GB DARTFORD KENT DA2 6QY
US N. GRANBY, CT 06060
FR 92974 MASSACHUSETTS 01730-9125
FR 6191 PARIS - LA DEFENSE CEDEX
ES 8191 RUBI
GB WOKINGHAM RG41 5RB
FR 36353 LA TOUR DU PIN CEDEX
MC 98000 MONACO
DE 82152 MARTINSRIED MUNICH
GB ELSTEAD GU8 6LB
GB HUNTINGTON PE18 6EF

+1 908 423 1000
+31 76 581 66 60
+41 91 611 36 36
+44 1582 475 248
+44 1322 425 200
+1 860 653 5371
+1 781 533 2897
+33 1 58 58 00 02
+34 93 586 0520
+44 1189 448 000
+33 4 37 05 00 50
+377 97 98 65 20
+49 898 9927 0
+44 1252 704 500
+44 1480 432 243

MW ENCAP LTD
MWG-BIOTECH AG
NAEJA PHARMACEUTICALS
NANOGEN EUROPE BV
NATURE EDITORIAL CONTACTS

4 Dunlop Square SW Deans Industrial Estate
Anzinger Strasse 7
4290-91A Street
Steenovenweg 3
Porters South 4 Crinan Street

GB LIVINGSTON EH54 8
DE 85660 EBERSBERG
CA EDMONTON ALBERTA T6E 5V2
NL 5708 HN HELMOND
GB LONDON N1 9XW

+44 1506 416 881
+49 809 2828 90
1 780 462 40 44
+31 49 250 71 60
+44 2078 334 000

NAUTA FOUNDATION

www.chem.vu.nl/en/sec/far/NautaFoundation/frame.html ◀



NCE DISCOVERY LIMITED
NEOMPS
NEWFORM
NEWMAN LABELLING SYSTEMS LTD
NEWSON GALE LTD
NIKEM RESEARCH
NIMBUS BIOTECHNOLOGY
NONLINEAR DYNAMICS LTD
NORGINE LTD
NOTOX BV

The vision Center 5 Eastern Way Bury St Edmunds
7 Rue de Boulogne
Reugelstraat 2
Queens Road Barnet
Unit 6, Churchill Park Colwick
Via Zambelletti 25
Ellenburger Str. 4
Tyne House 26 Side
Chaplin House Widewater Place Moorhall Road
Hambakenwetering 7, PO BOX 3476

GB SUFFOLK IP32 7AB
FR 67100 STRASBOURG
BE 3320 HOEGAARDEN
GB LONDON EN5 4DL
GB NOTTINGHAM NG4 2HF
IT 20021 BARANZATE DI BOLLATE MILANO
DE 4317 LEIPZIG
GB NEWCASTLE UPON TYNE NE1 3JA
GB HAREFIELD MIDDLESEX UB9 6NS
NL 5203 DL 'S HERTOGENBOSCH

+44 1993 201 801
+33 3 88 79 08 79
+32 16 766 159
+44 2084 400 044
+44 1159 407 500
+39 02 356941
+49 341 4793 350
+44 1912 302 121
+44 1895 826600
+31 73 640 67 00

NOVARTIS PHARMA AG

Postfach CH - 4002 Basel
SWITZERLAND

www.novartis.com ◀

Tel: +41 61 324 11 11 - Fax: +41 61 696 86 76



Novartis is currently the fifth largest pharmaceutical company worldwide with about 75,000 employees. Novartis produces medicines in the areas of central nervous system drugs, cardiovascular drugs, anti-inflammatory and pain medicines, cancer drugs, immunosuppressive and dermatology agents.

NOVASCREEN
NOVASEP
NOVASEPTIC EQUIPMENT AB
NOVIANT
NOVO NORDISK A/S
NUAIRE INC
NUNC AS
NUTRINOVA NUTRITION GMBH
OMEGA PHARMA NV
OMNICHEM
OMNIVIZ INC.
ONIX SCIENTIFIC LTD
ORBISPHERE
ORGANON
ORGANOTECHNIE
OXFORD INSTRUMENTS
OXOID LTD
OZONIA LTD
P.A.R.I.S
PALAS GMBH
PALL LIFE SCIENCES
PANCHIM
PANNEVIS BV
PANVERA CORPORATION
PARKER HANFIFIN PLC
PARTICLE ANALYTICAL
PARTICLE MEASURING SYSTEMS INC
PAUL LIPKKE HANDELS GMBH
PECON-T&B PEITHER CONSULTING
PENWEST PHARMACEUTICALS LTD
PEPTISYNTHA SA
PERKINELMER
PERKINELMER BENELUX

7170 Standard Drive
Site Eiffel Boulevard de la Moselle BP 50
Rodians vag 7
Winselingsweg 12
Novo Allé
2100 Farnbrook Lane Plymouth
Postbox 280
Industriepark Hoechst
IZ De Prikels Vencoweg, 26
Fond Jean P.ques 8 Fleming
28 avenue de Grandchamp
Units 97/98 Silverbirn Sunderland Enterprise Park East
6 Route de Compois Case Postale 212
Po Box 20
27 Avenue Jean Mermoz
Tubney Woods
Wade Road
Stertzbachstrasse 1
21 Quai Du Clos des Roses
Greschbachstrasse 3B
600 South Wagner Road
28 Rue du Bois Chaland - Lisses CE 2950
Elektronweg 24 Box Postbus 6264 (3503 RG)
501 Charnay Dr
Chorwell Vale Shaw Cross Business Park
Agerm Alle 3
Enigma Business Park Grovewood Road
Willi Bruckner Strasse 1
Himmelreichstrasse 7
Church House 48 Church Street
Rue de Ransbeek 310
Imperiastraat 8
Research Park, Pontbeeklaan 57

US HANOVER, MARYLAND 21076-1334
FR 54340 POMPEY
SE 44934 NODINGE
NL 6541 AK NIJMEGEN
DK 2880 BAGSVAERD
US MINNESOTA 55447
DK 4000 ROSKILDE
DE 65926 FRANKFURT/MAIN
BE 9810 NAZARETH
BE 1348 LOUVAIN-LA-NEUVE
FR 78230 LE PECQ-SUR-SEINE
GB SUNDERLAND SR5 2TQ
CH 1222 VESENAZ/GENEVE
NL 5340 OSS
FR 93120 LA COURNEUVE
GB ABINGDON OX13 5QX
CH BASINGSTOKE RG24 8PW
DE DUBENDORF
FR 60200 COMPIEGNE
DE 76229 KARLSRUHE
US ANN ARBOR MI 48103-9019
FR 91029 EVRY CEDEX
NL 3542 AC UTRECHT
US MADISON, WI 53719-1236
GB DEWSBURY WF12 7RD
DK HORSHOLM
GB MALVERN WR14 1XZ
DE 56564 NEUWIED
DE 79650 SCHOPFHEIM
GB REIGATE RH2 0SN
BE 1120 BRUXELLES
BE 1930 ZAVENTEM
BE 1731 ZELLIK

+41 400 712 4410
+33 3 83 49 70 00
+46 30 397 520
+31 24 371 99 00
+45 4444 8888
+1 763 553 1270
+45 4636 9065
+49 693 0584 471
+32 9 381 02 00
+32 10 48 31 11
+33 139163089
+44 1915 166 516
+41 22 855 91 00
+31 412 661222
+33 1 49 92 87 50
+44 1865 393 200
+44 1256 841 144
+41 1 801 85 11
+33 3 4420 6130
+49 721 9621 30
+1 734 665 0651
+33 1 69 11 28 28
+31 30 248 24 11
+44 1924 487 000
+45 4576 3060
+44 1684 581 000
+49 263 1393 30
+49 762 2666 8666
+44 1737 222 323
+32 2 264 2213
+32 2 719 80 25
+32 2 481 85 30

PERCEPTIVE BIOSYSTEMS
PF&F LTD
PFANNENSCHMIDT K-W GMBH
PFEIFFER VACUUM LTD
PHARMACELSUS GMBH
PHARMACOPEIA DRUG DISCOVERY INC.
PHARMAFLEX LTD
PHARMALYTIC
PHARMAPLAN
PHARMASOL LTD
PHARMATECH LTD
PHARMION CORPORATION
PHASE-1 BIORESEARCH NV
PHILIP HARRIS SCIENTIFIC
PHOTON TECHNOLOGY INTERNATIONAL INC.
PHYTOCHEM REFERENZSUBSTANZEN
PHYTOS-LABORATORY
PLIVA D.D.
POLPHARMA
POLYMER LABORATORIES LTD
POLYPHOR LTD
PORVAIR PLC
PREANALYTIX
PRECISION LABELLING SYSTEMS LTD
PRESSPART MANUFACTURING LTD

Otto-von-Guericke-Ring 7
Atherton
Habichtsthorst 36
2-4 Cromwell Bus. Centre Howard Way Interchange Park
Science Park 2
Box 5350
49 Colbourne Avenue Nelson Park
Murray Business Centre Murray Road St Pauls Cray
Borkenberg 14
North Way Walworth Industrial Estate
Units 8 & 9 Coleshill Trading Estate
2525 28th St., Suite 200
Technologiepark 4
Novara House Excelsior Road Ashby Park
Unit M1, Rudford Industrial Estate Ford Road
Krumbacherstrasse 9
Reutier Strasse 56
Ulica Grada Vukovara 49
19 Pelpinska Street
Essex Road Church Streton
Gewerbestrasse 14
Riverside Industrial Estate Estuary Road, Norfolk
Feldbachstrasse
Plews Way Leeming Bar Industrial Estate
Whitebirk Industrial Estate

DE 65205 WIESBADEN-NORDENSTADT +49 612 2983 030
GB MANCHESTER M46 0LY +44 1942 896 966
DE 22459 HAMBURG +49 405 5586 60
GB NEWPORT PAGNELL MK16 9QS +44 1908 500 600
DE 66123 SAARBRUECKEN +49 681 3946 7510
US PRINCETON NJ 08543-5350 +1 609 452 3600
GB CRAMLINGTON NE23 9WD +44 1670 730 684
GB ORPINGTON-KENT BR5 3RE +44 1689 898 192
DE 61440 OBERURSEL +49 617 2976 300
GB ANDOVER SP10 5AZ +44 1264 363 117
GB COLESHILL B46 1HT +44 1675 467 636
US BOULDER CO 80301 +1 720 564 9100
BE 9052 GENT-ZWIJNAARDE +32 9 241 11 60
GB ASHBY DE LA ZOUCH LE65 1NG +44 8456 040 490
GB FORD BN18 0BF +44 1903 719 555
DE 89335 ICHENHAUSEN +49 731 9720 545
DE 89231 NEU-ULM +49 731 9743 90
HR 10000 ZAGREB +385 1 61 20 999
PL 83200 STAROGARD GDANSKI +48 58 563 21 21
GB SHROPSHIRE SY6 6AX +44 1694 723 581
CH 4123 ALLSCHWIL +41 61 486 98 98
GB KING'S LYNN PE30 2HS +44 1553 761 111
CH 8634 HOMBRECHTIKON +41 03 291 66 00
GB NORTHALLERTON DL7 9UL +44 1677 423 533
GB BLACKBURN BB1 5FR +44 1254 582 233

PRESTWICK CHEMICAL Inc.



Boulevard Gonthier d'Andernach, 67400 Illkirch
FRANCE

► **MARIE-LOUISE JUNG**
prestchem@prestwickchemical.fr
www.prestwickchemical.com

Tel: +33 3 69 20 16 00 - Fax: +33 3 69 20 16 17

Prestwick Chemical, located near Strasbourg, France, was founded by Professor C.G. Wermuth to assist scientists to discover drugs for promising targets by offering innovative smart libraries. It has since extended its activity to providing medicinal chemistry services and original research scaffolds to pharmaceutical and biotechnology companies, as well as academic research laboratories.

PRINTING INTERNATIONAL
PRO-C-EPT
PROLOG BIOCHEMIE GMBH
PROMATIC
PROMEGA BENELUX
PROPHARMA LTD
PROSPAN
PROSENSE BV
PROSKELIA S.A.S
PROTEX DEVELOPMENTS LTD

Ambachtenlaan 34
Industrial Rosteyne 4
Georg Heyken Strasse 14
Via Nazionale 55/11
Kenauweg 34 PO BOX 391
204 George Street
Neijverheidsweg 26
Bredaseweg 108a
102 Route de Noisy
Boy Lane

BE 9880 AALTER +32 9 325 85 85
BE 9060 ZELZATE +32 9 342 23 23
DE 21147 HAMBURG +49 407 9702 0
IT 40067 RASTIGNANO +39 5 174 48 47
NL 2300 AJ LEIDEN +31 71 532 42 44
GB GLASGOW G1 1XW +44 1415 484 955
BE 9820 MERELBEKE +32 9 231 37 04
NL 4902 NS OOSTERHOUT +31 162 471 485
FR 93230 ROMAINVILLE +33 1 49 42 46 46
GB HALIFAX HX3 5AF +44 1422 322 623

PROUS SCIENCE



Provenza, 388, 08025 Barcelona
SPAIN

► **Dr. JOSEP PROUS, Jr., Executive Vice President**
support@prous.com
www.prous.com

Tel: +34 93 459 22 20 - Fax: +34 93 458 15 35

About Prous Science, a Thomson Scientific business

For more than 40 years, Prous Science has been a trusted source of information on which science depends to discover safer and more effective medicines. Prous Science products have evolved through the years from print journals to sophisticated electronic products incorporating the latest advances in IT. The business has complemented its drug discovery solutions with a series of key partnerships to widen the dissemination of medical education worldwide by fostering relationships with key medical associations and centers of excellence worldwide. Prous Science was acquired by Thomson Scientific, a leading information solutions provider, in September 2007. For more information visit www.prous.com and scientific.thomson.com

PROVALIS
PRTM
PURAC BIOCHEM BV
PURETECH PROCESS SYSTEMS LTD
QUIGEN SA
Q-ONE BIOTECH LTD
QUALITY ASSISTANCE
QUALITY CONTROL NORTH WEST

Units 1-4 Craven Court Stanhope Road
25 The Quadrant Abingdon Science Park Abingdon
Arksedijk 46 PO BOX 21
Aztec House Perrywood Business Park Salfords
3 Avenue du Canada LP 809
Todd Campus West of Scotland Science Park
Technoparc de Thudinie 1
Stepping Hill Hospital Poplar Grove

GB CAMBERLEY GU15 3BW +44 1276 678 870
GB OXFORD OX14 3YS +44 1235 555 500
NL 4200 AA GORINCHEM +31 18 369 58 10
GB REDHILL RH1 5DZ +44 1737 378 000
FR 91974 COURTABOEUF CEDEX +33 1 60 92 09 20
GB GLASGOW G20 0XA +44 1419 469 999
BE 6536 DONSTIENNES +32 71 53 47 81
GB STOCKPORT SK2 7JE +44 1614 195 011

PYXIS DISCOVERY

Delftechpark 26, 2628 XH Delft
THE NETHERLANDS

ALEXANDRINE CHERONET ◀
ac@pyxis-discovery.com
www.pyxis-discovery.com

Tel: +31 15 2600972 - Fax: +31 15 2600973



Small Molecules! Pyxis Discovery offers chemistry based lead discovery services to the global pharmaceutical industry with three major focuses: the development of Smart Libraries (lead-like molecules and fragments), a Proteases lead discovery service using a proprietary screening platform and a fragment based lead discovery service.

QUANTACHROME CORP.	1900 Corporate Drive Boynton Beach	US	FLORIDA 33426	+1 561 731 4999
QUINTILES LTD	Res. Av. South Heriot-Watt Univ. Research Park Riccarton	GB	EDINBURGH EH14 4AP	+44 1314 512 074
QUMAS	Mainport House Monahan's Road	IE	CORK	+353 21 491 5100
RADLEYS	Shire Hill, Saffron Walden	GB	ESSEX CB11 13AZ	+44 0 1799 513320
RADLEYS DISCOVERY TECHNOLOGIES	Shire Hill, Saffron Walden	GB	ESSEX, CB11 3AZ	+44 1799 513320
RECKITT BENCKISER PLC	103-105 Bath Road	GB	SLOUGH BERKS SL1 3UH	
REMP AG	Weststrasse 12	CH	3672 OBERDIESSBACH	+41 31 770 70 70
REMYND	Minderbroederstraat, 12	BE	3000 LEUVEN	+32 16 33 25 27
RENTSCHLER BIOTECHNOLOGIE GMBH & CO. KG	Erwin-Rentschler-Strasse 21	DE	88471 LAUPHEIM	+49 739 2701 555
RHEIN BIOTECH GMBH	Eichsfelder Strasse 11	DE	40595 DUSSELDORF	+49 211 7584 50
RHODIA SA	26 quai Alphonse Le Gallo	FR	92512 BOULOGNE-BILLANCOURT CEDEX	+33 1 55 38 40 00
RICERCA	7528 Auburn Road Concord	US	OHIO 44077	+1 440 357 3341
ROBERT BOSCH GMBH ABT. FV/FLC	Stuttgarter Strasse 130 PO BOX 1127 (D-71301)	DE	71332 WAIBLINGEN	+49 715 1140 1
ROBINSON BROTHERS LTD	Phoenix Street	GB	WEST BROMWICH B70 0AH	+44 1215 532 451

ROCHE

F. Hoffmann-La Roche Ltd.
4070 Basel
SWITZERLAND

basel.personalmarketing@roche.com ◀
http://careers.roche.com



Headquartered in Basel, Switzerland, Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As the world's biggest biotech company and an innovator of products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people's health and quality of life. Roche is the world leader in in-vitro diagnostics and drugs for cancer and transplantation, a market leader in virology and active in other major therapeutic areas such as autoimmune diseases, inflammation, metabolic disorders and diseases of the central nervous system.

ROMACO UK LTD	Ermine Business Park Lakeview Court	GB	HUNTINGDON PE29 6WD	+44 1480 435 050
ROMMELAG AG	Fabrikweg 16 Postfach / PO BOX	CH	5033 BUCHS	+41 62 834 55 55
ROTORK CONTROL & SAFETY LTD	Chaul End Lane	GB	LUTON LU4 8EZ	+44 1582 399 499

ROYAL SOCIETY OF CHEMISTRY

MRS MELANIE CHARLES ◀
marketing@rsc.org
www.rsc.org/publishing

Tel: +44 (0)1223 420066 - Fax: +44 (0)1223 420247



We are one of the world's leading scientific publishers, offering an exceptional range of peer-reviewed journals, magazines, books, databases and publishing services to the chemical science community. We also offer a range of products specific to the medicinal chemistry community.

RUTGERS ORGANICS GMBH	Sandhofer Strasse 96	DE	68305 MANNHEIM	+49 621 7654 046
SANKYO CO LTD	3-5-1, Nihonbashi Hon-cho, Chuo-ku	JP	103-8426 TOKYO	+81 3 5255 7111
SANOFI-AVENTIS	174, av. de France	FR	75013 PARIS	+33 1 53 77 4000
SANYO GALLENKAMP PLC	Monarch Way Belton Park	GB	LOUGHBOROUGH LE11 5XG	+44 1509 265 265
SARTORIUS AG	Wender Landstrasse 94-108	DE	37075 GOETTINGEN	+49 551 308 3318

SCANBECH LTD
SCHARFE SYSTEM GMBH
SCHENK PROCESS GMBH
SCHERING AG
SCHERING PLOUGH INTERNATIONAL
SCHMETTERLING ASSOCIATES
SCHOTT GLAS
SCIENCE INTERNATIONAL
SCIENCE MARKETING INTERNATIONAL
SCIENTIFIC UPDATE
SCITEGIC UK
SCYNEKIS
SEAL LINE SPA
SENN CHEMICALS AG
SENSOR TECHNOLOGY LTD
SEPHA LTD
SEQUENOM
SERONO INTERNATIONAL S.A.
SERVIER

44 Arkwright Road Astmoor Industrial Estate
Kramerstrasse 22 Baden-Wurtemberg
Landwehrstrasse 55
Mollerstr. 178
2000 Galloping Hill Road
11A Dawson Place
Hattenbergstrasse 10
Bateman House 82-88 Hills Road
Units 1 & 2/The Steadings Maisemore Court
Maycroft Place Stone Cross Mayfield
11 Hobbs Court Jacob Street
Post Office Box 12878 Research Triangle Park
Via Bernarde 11
Industriestrasse 12
PO BOX 36
Jubilee Road
3595 John Hopkins Court
15bis, chemin des Mines Case postale 54
22 rue Garnier

GB RUNCORN WA7 1NU
DE 72764 REUTLINGEN
DE 64273 DARMSTADT
DE 13353 BERLIN
US KENILWORTH N.J. 07033-0530
GB LONDON W2 4TD
DE 55122 MAINZ
GB CAMBRIDGE CB2 1LQ
GB GLOUCESTER GL2 8EY
GB EAST SUSSEX TN20 6EW
GB LONDON SE1 2BG
US NC 27709-2878
IT 36040 MONTEGALDELLA
CH 8157 DIELSDORF
GB BANBURY OX15 6JB
GB NEWTOWNARDS BT23 4XQ
US SAN DIEGO, CA 92121-1331
CH 1211 GENEVA 20
FR 92578 NEUILLY-SUR-SEINE CEDEX

+44 1928 561 747
+49 712 1387 860
+49 615 1321 028
+49-30-468-11 11
+1 (908) 298-4000
+44 20 7221 9559
+49 613 1662 172
+44 1223 326 500
+44 1452 310 210
+44 1435 873062
+44 207 394 3592
+1 919 544 8600
+39 4 447 37 200
+41 1 854 90 54
+44 1295 730 746
+44 2891 824 252
+1 858 202 9000
+41 22 739 3000
+33 1 55 72 60 00

INSTITUT DE RECHERCHES SERVIER



3 rue de la Republique
F 92150 SURESNES
FRANCE

www.servier.fr


SETARAM SA
SHAW PACKAGING SERVICES
SHIMADZU UK
SHIONOGI QUALICAPS SA
SILVERSON MACHINES LTD
SIMPORT
SINTOFARM SPA
SIRIUS ANALYTICAL INSTRUMENTS LTD
SLEEVER INTERNATIONAL
SOLUTIA EUROPE

7 Rue de l'Oratoire
1 Privett Place
Mill Court Featherstone Road
Calle de la Granja 49
Waterside
Bernard Pilon 2588 Beloeil
Via Togliatti 5
Riverside Forest Row Business Park
5 Avenue Arago Box BP 27
Rue Laid Burniat 3

FR 69300 CALUIRE
GB GOSPORT PO12 3SG
GB MILTON KEYNES MK12 5RE
ES 28108 ALCOBENDAS /MADRID
GB CHESHAM HP5 1PQ
CA QUEBEC J3G 4S5
IT 42016 GUASTALLA
GB FOREST ROW RH18 5DW SUSSEX
FR 91421 MORANGIS
BE 1348 LOUVAIN-LA-NEUVE

+33 4 72 10 25 25
+44 2392 583 256
+44 1908 552 200
+34 91 663 0800
+44 1494 786 331
+1 450 464 1723
+39 5 228 31 321
+44 1342 820 720
+33 1 69 74 75 76
+32 10 48 12 11

SOLVAY PHARMACEUTICALS BV



P.O. Box 900, 1380 DA Weesp
THE NETHERLANDS

Telephone +31 (0)294 47 70 00
www.solvaypharmaceuticals.com


SOPACHEM
SPC
SPECTRAL INSTRUMENTS

Begoniestraat 17
287 Rue des Mercieries ZI Perica Le Plateau
1802 West Grant Road Suite 110

BE 9810 EKE
FR 69140 RILLIEUX LA PAPE
US TUCSON AZ 85745

+32 2 474 50 70
+33 4 78 88 79 56
+1 520 884 8821

SPECS



Kluyverweg 6, NL-2629 HT, Delft
THE NETHERLANDS

► **EILT VAN DER STAR**
info@specs.net
www.specs.net

Tel: +31 15 2518 111 - Fax: +31 15 2518 181

Specs is one of the leading suppliers of screening compounds, building blocks and natural products. We offer a wide range of services such as laboratory services, cheminformatics, compound sourcing and complete library management.

SPECTRO	Boschstrasse 10	DE	47533	KLEVE	+49 282 1892 2146
SPIROFLOW LTD	Lincoln Way	GB		CLITHEROE BB7 1QG	+44 1200 422 525
SPOTFIRE AB	F'rsta Langgatan 26	SE	41328	GOTEBORG	+46 31 704 1500
SPRAYING SYSTEMS LTD	Unit 4 Bourne Mill Industrial Estate Guilford Road	GB		FARNHAM GU9 9PS	+44 1252 727 200
SPSS SCIENTIFIC SOFTWARE GMBH	Schimmelbuschstrasse 25	DE	40699	ERKRATH	+49 210 4954 61
STABLE MICRO SYSTEMS	Vienna Court Lammas Road	GB		GODALMING GU7 1YL	+44 1483 427 345
STALLERGENES S.A.	6 Rue Alexis de Tocqueville	FR	92183	ANTONY CEDEX	+33 1 55 59 20 00
STANHOPE-SETA	Park Close Englefield Green	GB		EGHAM TW20 0XD	+44 1932 564 391
STEDIM SA	ZI Des Paluds Avenue de Jouques Box BP 1051	FR	13781	AUBAGNE CEDEX	+33 4 42 84 56 00
STELLA KUNSTSTOFFTECHNIK GMBH	H.J Muller Strasse 4	DE	65343	ELTVILLE	+49 612 3600 80
STELMI TRADING INTERNATIONAL	22 Avenue des Nations BP 55415 Villepinte	FR	95944	ROISSY CHARLES DE GAULLE CEDEX	+33 (0) 1 48 63 56 56
STEROP PHARMACOBEL	Avenue de Scheut 46-50	BE	1070	BRUXELLES	+32 2 527 33 63
STRATAGENE	Gebouw California Hogehilweg 15	NL	1101 CB	AMSTERDAM	+31 800 96 078
STRUCTURAL GENOMIX	10505 Roselle Street	US		SAN DIEGO, CA 92121	+1 858 558 4850
SUMMIT PHARMACEUTICALS EUROPE LTD	Vintner's Place 68 Upper Thames Street	GB		LONDON EC4V 3BJ	+44 2072 463 800
SUNESIS PHARMACEUTICALS INC.	341 Oyster Point Boulevard.	US		SOUTH SAN FRANCISCO CA 94081	+1 650 266 3628
SVUS AS PHARMA	Skroupova 957	CZ	50192	HRADEC KRALOVE	+42 49 673 116
SWISSVAC LTD	Marish Wharf St Mary's Road	GB		LANGLEY SL3 6DA	+44 1753 546 777
SYMBOL TECHNOLOGIES LTD	Symbol Place	GB		WINERSH TRIANGLE RG41 5TP	+44 1189 457 000
SYNAPSE INFORMATION RESOURCES INC	1247 Taft Avenue Endicott	US		NEW-YORK 13760	+1 607 748 4145
SYNERGIX	Technology Park, Malha Bldg 1	IL	91487	JERUSALEM	+9 72 2 648 03 96
SYNOPTICS LTD	Beacon House Nuffield Road	GB		CAMBRIDGE CB4 1TF	+44 1223 727 100
SYNTAPHARM	Xantener Strasse 1-3 PO BOX 101763 (D-45417)	DE	45479	MUELHEIM AN DER RUHR	+49 208 3069 2000
T GIUSTI LTD	Rixon Road Finedon Road Industrial Estate	GB		WELLINGBOROUGH NN8 4BA	+44 1933 229 933
TA INSTRUMENTS	Brusselssteenweg 500	BE	1731	ZELLIK	+32 2 706 00 80
TARO PHARMACEUTICAL INDUSTRIES LTD	Italy House Euro Business Park	IL		YAKUM 60972	+972 9 9711 800
TECAN GROUP LTD	Seestrasse 103	CH	8708	MAENNEDORF	+41 1 922 88 88
TELSONIC AG	Industriestrasse	CH	9552	BRONSCHEFEN	+41 71 913 98 88
TELSTAR SA	Josep Tapiolas 120 PO BOX 317Terassa	ES	8226	BARCELONA	+34 93 736 1600
TEMLER PHARMA GMBH & CO KG	Temmlerstrasse 2 PO BOX 2269 (D-35010)	DE	35039	MARBURG	+49 642 1494 0
THALES ENGINEERING & CONSULTING	25 Rue du Pont des Halles Chevilly-Larue	FR	94666	RUNGIS CEDEX	+33 1 56 30 63 93
THE FITZPATRICK CO. EUROPE NV	Entrepotstraat 8	BE	9100	SINT-NIKLAAS	+32 3 777 72 08
THE PROCESS CONTROL CO.	Griffin Lane	GB		AYLESBURY HP19 8BF	+44 1296 484 877
THE WOLFSON CENTRE FOR BULK	University of Greenwich Wellington Street Woolwich	GB		LONDON SE18 6PF	+44 2083 318 646
THERABEL PHARMA NV-SA	Rue Eglise Van Ophem 108	BE	1180	BRUXELLES	+32 2 370 46 11
THERMAL TRANSFERT LTD	Thermal Transfert House Norfolk Square	GB		GLOSSOP SK13 7AG	+44 1457 854 341
THERMO FINNIGAN	355 River Oaks Parkway	US		SAN JOSE, CA 95134-1991	+1 408 965 6000
THIEME PUBLISHERS	R idigerstrasse 14	DE	70469	STUTTGART	+49 711 8931 772
TIMTEC	100 Interchange Boulevard	US		NEWARK, DE 19711	+1 302 292 8500
TINTOMETER LTD	The Colour Laboratory Waterloo Road	GB		SALISBURY SP1 2JY	+44 1722 327 242
TNO PHARMA	Utrechtseweg 48 PO BOX 360	NL	3700 AJ	ZEIST	+31 30 694 48 44
TCCRIS COOKSON LTD	Northport, Fourth Way, Avonmouth	GB		BRISTOL BS11 8TA,	+44 117 9826551
TOMMY NIELSEN	Malervvej 6 Box 3080	DK	6710	ESBJERG V	+45 7515 3200
TOPOTARGET	Symbion Science Park Fruebjergvej 3	DK	2100	COPENHAGEN	+45 3917 9493
TORIT DCE	Humberstone Lane	GB		THURMASTON LE4 8HP	+44 1162 696 161
TOSOH BIOSEP GMBH	Zettaching 6	DE	70567	STUTTGART	+49 711 1325 70
TRAMEDICO BV	Pampuslaan 186	NL	1382 JS	WEESP	+31 294 - 46 11 22
TRENKER LABORATORIES	Avenue Dolez 480-482	BE	1180	BRUXELLES	+32 2 374 02 53
TRIPOS DISCOVERY RESEARCH LTD	Bude- Stratton Business Park	GB		BUDE CORNWALL EX23 8LY	+1 314 647 1099
TROX LTD	Caxton Way	GB		THETFORD IP24 3SQ	+44 1842 754 545
TYCO HEALTHCARE	15 Hampshire Street	US		MANSFIELD MA 02048	+1 800 962-9888

UCB

Allée de la Recherche, 60 - 1070 Brussels
BELGIUM

www.ucb-group.com

Tel: +32 2 559 99 99 - Fax: +32 2 559 99 00



UCB is a leading global biopharmaceutical company dedicated to the research, development and commercialisation of innovative pharmaceutical and biotechnology products in the fields of central nervous system disorders, allergy/respiratory diseases, immune and inflammatory disorders and oncology. UCB focuses on securing a leading position in severe disease categories. Employing over 8,300 people in over 40 countries, UCB achieved revenue of 2.3 billion euro in 2005. UCB is listed on the Euronext Brussels Exchange and its worldwide headquarters are located in Brussels, Belgium.

ULTRA-VIOLET PRODUCTS LTD	Unit 1 Trinity Hall Farm Estate Nuffield Road	GB		CAMBRIDGE CB4 1TG	+44 1233 420 022
UNIQ FILTRATION TECHNOLOGY AS	Narvikvej 11 PO BOX 138	DK	4900	NAKSKOV	+45 5495 8700
USON EUROPE	Western Way	GB		BURY ST EDMUNDS IP33 3SZ	+44 1284 574 321
VALIDATION IN PARTNERSHIP LTD	Adelphi Mill Grimsshaw Lane	GB		BOLLINGTON SK10 5JB	+44 1625 572 777
VENCHEM LTD	Knotts Lane Works	GB		COLNE BB8 8AA	+44 1282 861 198
VIATRUS GMBH & CO. KG	Weism illerstrasse 45	DE	60314	FRANKFURT AM MAIN	+49 69 40 01 01
VINDON SCIENTIFIC LTD	Kiln Green Diggle	GB		OLDHAM OL3 5JY	+44 1457 876 616
VOETSCH INDUSTRIETECHNIK GMBH	Greizer Strasse 41-49	DE	35447	REISKIRCHEN-LINDENSTRUTH	+49 640 8847 3
VOELBUSCH GMBH	Bleichturmstrasse 11 Box Postfach 189 (A-1051)	AT	1050	VIENNA	+43 1 546 610
VRJUE UNIVERSITEIT LACDR	Faculty of Science, Vrije Universiteit De Boelelaan 1083	NL	1081 HV	AMSTERDAM	+31 20 444 75 79
WAKO CHEMICALS GMBH	Nissanstrasse 2	DE	41468	NEUSS	+49 213 1311 100
WILEY-VCH VERLAG GMBH & CO. KGAA	Boschstrasse 12	DE	69469	WEINHEIM	+49 6201 606 400

WYETH



► **MAGID ABOU-GHARBIA**, Ph.D., Sr. VP, Chemical & Screening Sciences
www.wyeth.com
 Tel: 732-274-4522 - Fax: 732-274-4500

Wyeth Pharmaceuticals, a division of Wyeth, has leading products in the areas of women's health care, infectious disease, gastrointestinal health, central nervous system, inflammation, transplantation, hemophilia, oncology, vaccines and nutritional products. Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products and non-prescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.

WYETH PHARMACEUTICALS
 YAMADA
 YMC EUROPE GMBH
 ZAMBON GROUP SPA
 ZANCHETTA EC SRL
 ZENTARIS GMBH
 ZINSSER ANALYTIC

5 Giralda Farms
 Aquamarynstraat 50
 Alte Raesfelder Strasse 6
 Via della Chimica 9
 Via della Contea 24 Montecarlo
 Weism Illerstr. 45
 Eschborner Landstrasse 135

US MADISON NJ 07940
 NL 7554 NS HENGLO
 DE 46514 SCHERMBECK
 IT 36100 VICENZA
 IT 55010 S.SALVATORE
 DE 60314 FRANKFURT
 DE 60489 FRANKFURT

+31 74 242 20 32
 +49 285 6919 20
 +39 0444 968911
 +39 5 832 17 1
 +49 (0) 69 42 602 3423
 +49 697 8910 60

NAEJA

Pre-Clinical Pharmaceutical R&D, designed for fast ROI.

With the expertise and passion of our multidisciplinary teams utilising an ever expanding knowledge base, we're committed to building faster and more efficient discovery pipelines. **NAEJA, building chemistry for life.**

COMPUTATIONAL SERVICES
 PROCESS DEVELOPMENT
 MICROBIOLOGY
 DRUG METABOLISM

MEDICINAL CHEMISTRY
 SCALE UP
 PHARMACOKINETICS

NAEJA
 Fast Evolution

001.780-462-4044
www.naeja.com
info@naeja.com

4290-91 A Street
 Edmonton, Alberta
 Canada T6E 5V2

Medicinal Chemistry in Europe - Yearbook 2008 is edited by:




Scientific Conference Producers



The Art of Global Discovery Chemistry



CHEMBRIDGE CORPORATION IS THE WORLD'S
LEADING GLOBAL DISCOVERY CHEMISTRY CRO AND PREMIER
PROVIDER OF ADVANCED SCREENING LIBRARIES FOR SMALL
MOLECULE DRUG DISCOVERY. WWW.CHEMBRIDGE.COM



THE ART OF GLOBAL DISCOVERY CHEMISTRY



CHEMBRIDGE CORPORATION IS THE WORLD'S
LEADING GLOBAL DISCOVERY CHEMISTRY CRO AND PREMIER
PROVIDER OF ADVANCED SCREENING LIBRARIES FOR SMALL
MOLECULE DRUG DISCOVERY. WWW.CHEMBRIDGE.COM